Anti-TIGIT-anti-PVRIG bispecific antibody, pharmaceutical composition and application thereof
Patent Information
- Application Number
- CN202380031275.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-04-02
- Filing Date
- 2023-03-31
- Publication Date
- 2024-11-12
AI Technical Summary
In the development of bispecific antibodies, there are problems such as complex preclinical evaluation models, low expression levels, poor stability, complex processes, and large differences in quality control, which have affected the development of bispecific antibodies targeting TIGIT and PVRIG. progress.
A new bispecific antibody was developed, which includes a first protein functional domain targeting PVRIG and a second protein functional domain targeting TIGIT, with good affinity and biological activity, designed through specific amino acid sequences and connecting fragments , forming an efficient antibody structure.
It achieves efficient combination and blocking of TIGIT and PVRIG, significantly enhances the killing effect of NK cells on tumor cells, has low toxic and side effects, and shows good efficacy in vivo and in vitro.
Smart Images

Figure CN118946592A_ABST
Abstract
Description
Anti-TIGIT-anti-PVRIG bispecific antibodies, pharmaceutical compositions and uses thereof Technical Field
[0001] The present invention belongs to the field of biomedicine and relates to an anti-TIGIT-anti-PVRIG bispecific antibody, a pharmaceutical composition thereof and uses. Background Art
[0002] T cell immunoreceptor with Ig and ITIM domains (TIGIT, also known as WUCAM, Vstm3 or VSIG9) is a novel immunoinhibitory receptor belonging to the PVR receptor family and is expressed by activated CD8+ T and CD4+ T cells, natural killer (NK) cells, regulatory T cells (Tregs) and follicular helper T cells.
[0003] The poliovirus receptor related immunoglobulin domain-containing protein (PVRIG, also known as CD112R) belongs to the PVR receptor family. Its extracellular region has an IgV domain and its intracellular region contains an ITIM (Immunoreceptor tyrosine-based inhibitory motif) domain. It is mainly expressed on natural killer (NK) cells and T cells.
[0004] PVRIG or its ligand PVRL2 is highly expressed in lung cancer, kidney cancer, endometrial cancer, breast cancer, skin cancer and their tumor microenvironment, and PVRIG is also highly expressed on NK cells of prostate cancer patients (Whelan S, et al. Cancer Immunol Res. 2019; 7(2): 257-268.). In addition, PVRIG is co-expressed with the exhausted CD8+ T cell marker TIGIT and PD-1 molecules, suggesting that PVRIG expression has certain tumor specificity and may be related to the activation / exhaustion state of TILs in the tumor (Whelan S, et al. Cancer Immunol Res. 2019; 7(2): 257-268.). WO2021180205A1 reports that anti-PVRIG antibodies can be used for the prevention and treatment of lung cancer, breast cancer, ovarian cancer, kidney cancer, gastric cancer, endometrial cancer, head and neck cancer, etc.
[0005] TIGIT / PVRIG jointly participate in a complex regulatory network: CD226 (DNAM-1) is an activating receptor on T / NK cells, which mediates the activation signal of T / NK cells by binding to CD155 and CD112; while TIGIT and PVRIG are inhibitory receptors on T / NK cells, which are upregulated after the cells are activated, and independently mediate inhibitory signals by binding to the two ligands CD155 and CD112, respectively. At the same time, they also compete with CD226 for ligands and block the stimulation signals it transmits, thereby achieving negative regulation of immune cell function.
[0006] Researchers have used antibodies to block the interactions of TIGIT / CD155 and PVRIG / CD112, respectively, to enhance the cytotoxicity of NK cells against tumor cells. However, the combination of PVRIG and TIGIT blocking monoclonal antibodies can further enhance the killing effect of NK cells against breast cancer cells (Xu F et al., Blockade of CD112R and TIGIT signaling sensitizes human natural killer cell functions. Cancer Immunol Immunother. 2017 Oct; 66(10): 1367-1375.). In vitro functional studies of T cells have shown that TIGIT antibodies and PVRIG antibodies can increase T cell proliferation or IFN-γ secretion, respectively, and the combination of the two can produce additive or synergistic effects, further improving T cell function (Whelan S et al., PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8+T-cell Function. Cancer Immunol Res. 2019 Feb; 7(2): 257-268.). In a gene knockout mouse model, PVRIG antibodies can reduce tumor growth in TIGIT- / - mice, and tumor growth control in PVRIG and TIGIT double knockout mice is further improved compared to single knockout mice (Kathryn Logronio et al., COM902, a Novel Therapeutic Antibody Targeting TIGIT Augments T Cell Function and the Activity of PVRIG Pathway Blockade In Vitro and In Vivo. SITC 2019.). These experimental data demonstrate that TIGIT / CD155 and PVRIG / CD112 are two independent, non-redundant T cell negative regulation pathways. Simultaneously targeting both TIGIT and PVRIG is expected to better release T cell activation signals generated by CD226 in tumor treatment.
[0007] SHR-2002, developed by Hengrui Medicine, is the first and only TIGIT / PVRIG dual-target antibody of its kind to enter clinical development so far. It was approved for clinical use in early December 2021 and is currently in Phase I clinical trials for cancer treatment.
[0008] Simultaneous targeting of both TIGIT and PVRIG has demonstrated promising results in both in vitro and in vivo experiments. Bispecific antibodies, which can simultaneously bind to two antigens or antigenic epitopes, possess both specificity and bifunctionality, and have become a research hotspot in the field of antibody engineering. However, the development of bispecific antibodies has been hampered by complex preclinical evaluation models, low expression levels, poor stability, complex processes, and significant variability in quality control.
[0009] Therefore, there is still an urgent need in this field to develop a bispecific antibody targeting both TIGIT and PVRIG that has good specificity, good efficacy and is easy to prepare.
[0010] Summary of the Invention
[0011] Through in-depth research and creative work, the present inventors have developed novel bispecific antibodies. Surprisingly, the present inventors have discovered that the bispecific antibodies of the present invention possess excellent affinity and biological activity, and have anti-tumor potential. Consequently, the present inventors provide the following invention:
[0012] One aspect of the present invention relates to a bispecific antibody comprising:
[0013] Targeting the first protein domain of PVRIG, and
[0014] Targeting a second protein domain that is distinct from PVRIG (e.g., TIGIT);
[0015] in:
[0016] The first protein functional region is an anti-PVRIG immunoglobulin or an antigen-binding fragment thereof;
[0017] The heavy chain variable region of the anti-PVRIG immunoglobulin comprises HCDR1 with an amino acid sequence as shown in SEQ ID NO: 25, HCDR2 with an amino acid sequence as shown in SEQ ID NO: 26, and HCDR3 with an amino acid sequence as shown in SEQ ID NO: 27; and
[0018] The light chain variable region of the anti-PVRIG immunoglobulin comprises LCDR1 with an amino acid sequence as shown in SEQ ID NO: 22, LCDR2 with an amino acid sequence as shown in SEQ ID NO: 23, and LCDR3 with an amino acid sequence as shown in SEQ ID NO: 24.
[0019] In some embodiments of the present invention, the bispecific antibody is an anti-TIGIT-anti-PVRIG bispecific antibody, also expressed as an anti-PVRIG-anti-TIGIT bispecific antibody, referred to as the bispecific antibody of the present invention.
[0020] In some embodiments of the present invention, in the bispecific antibody, the second protein functional region is an anti-TIGIT immunoglobulin or an antigen-binding fragment thereof, wherein:
[0021] The heavy chain variable region of the anti-TIGIT immunoglobulin comprises an HCDR1 with an amino acid sequence as shown in SEQ ID NO: 13, an HCDR2 with an amino acid sequence as shown in SEQ ID NO: 14, and an HCDR3 with an amino acid sequence as shown in SEQ ID NO: 15; and the light chain variable region of the anti-TIGIT immunoglobulin comprises an LCDR1 with an amino acid sequence as shown in SEQ ID NO: 16, an LCDR2 with an amino acid sequence as shown in SEQ ID NO: 17, and an LCDR3 with an amino acid sequence as shown in SEQ ID NO: 18;
[0022] or,
[0023] The heavy chain variable region of the anti-TIGIT immunoglobulin comprises HCDR1 as shown in SEQ ID NO:19, HCDR2 as shown in SEQ ID NO:20, and HCDR3 as shown in SEQ ID NO:21; and the light chain variable region of the anti-TIGIT immunoglobulin comprises LCDR1 as shown in SEQ ID NO:22, LCDR2 as shown in SEQ ID NO:23, and LCDR3 as shown in SEQ ID NO:24.
[0024] The variable regions of the light and heavy chains determine antigen binding; the variable region of each chain contains three hypervariable regions, called complementarity determining regions (CDRs) (the CDRs of the heavy chain (H) include HCDR1, HCDR2, and HCDR3, and the CDRs of the light chain (L) include LCDR1, LCDR2, and LCDR3. In some embodiments of the present invention, HCDR1-HCDR3 and LCDR1-LCDR3 are defined or numbered with reference to U.S. Patent Publication US20210380669A1 or the literature Lu. et al (Deamidation and isomerization liability analysis of 131 clinical-stage antibodies, MABS, 2019, VOL.11, NO.1, 45–57, DOI: 10.1080 / 19420862.2018.1548233).
[0025] In some embodiments of the present invention, in the bispecific antibody, the antigen-binding fragment is independently a single-chain antibody or a half-molecule monovalent antibody (IgG half molecule, IgG-HM).
[0026] In some embodiments of the present invention, the bispecific antibody, wherein
[0027] The first protein functional region is an anti-PVRIG immunoglobulin, and the second protein functional region is an anti-TIGIT single-chain antibody; wherein:
[0028] The heavy chain variable region of the anti-PVRIG immunoglobulin comprises HCDR1 as shown in SEQ ID NO: 25, HCDR2 as shown in SEQ ID NO: 26, and HCDR3 as shown in SEQ ID NO: 27; and the light chain variable region of the anti-PVRIG immunoglobulin comprises LCDR1 as shown in SEQ ID NO: 22, LCDR2 as shown in SEQ ID NO: 23, and LCDR3 as shown in SEQ ID NO: 24; and
[0029] The anti-TIGIT single-chain antibody, whose heavy chain variable region comprises HCDR1 with an amino acid sequence as shown in SEQ ID NO: 13, HCDR2 with an amino acid sequence as shown in SEQ ID NO: 14, and HCDR3 with an amino acid sequence as shown in SEQ ID NO: 15; and the light chain variable region of the anti-TIGIT immunoglobulin comprises LCDR1 with an amino acid sequence as shown in SEQ ID NO: 16, LCDR2 with an amino acid sequence as shown in SEQ ID NO: 17, and LCDR3 with an amino acid sequence as shown in SEQ ID NO: 18; or
[0030] The anti-TIGIT single-chain antibody, whose heavy chain variable region comprises HCDR1 as shown in SEQ ID NO:19, HCDR2 as shown in SEQ ID NO:20, and HCDR3 as shown in SEQ ID NO:21; and the light chain variable region of the anti-TIGIT immunoglobulin comprises LCDR1 as shown in SEQ ID NO:22, LCDR2 as shown in SEQ ID NO:23, and LCDR3 as shown in SEQ ID NO:24.
[0031] In some embodiments of the present invention, the bispecific antibody, wherein
[0032] The first protein functional region is an anti-PVRIG single-chain antibody, and the second protein functional region is an anti-TIGIT immunoglobulin; wherein:
[0033] The heavy chain variable region of the anti-PVRIG single-chain antibody comprises an HCDR1 with an amino acid sequence as shown in SEQ ID NO: 25, an HCDR2 with an amino acid sequence as shown in SEQ ID NO: 26, and an HCDR3 with an amino acid sequence as shown in SEQ ID NO: 27; and the light chain variable region of the anti-PVRIG immunoglobulin comprises an LCDR1 with an amino acid sequence as shown in SEQ ID NO: 22, an LCDR2 with an amino acid sequence as shown in SEQ ID NO: 23, and an LCDR3 with an amino acid sequence as shown in SEQ ID NO: 24; and
[0034] The anti-TIGIT immunoglobulin, wherein the heavy chain variable region comprises HCDR1 as shown in SEQ ID NO: 13, HCDR2 as shown in SEQ ID NO: 14, and HCDR3 as shown in SEQ ID NO: 15; and the light chain variable region of the anti-TIGIT immunoglobulin comprises LCDR1 as shown in SEQ ID NO: 16, LCDR2 as shown in SEQ ID NO: 17, and LCDR3 as shown in SEQ ID NO: 18; or
[0035] The anti-TIGIT immunoglobulin has a heavy chain variable region comprising an HCDR1 with an amino acid sequence as shown in SEQ ID NO: 19, an HCDR2 with an amino acid sequence as shown in SEQ ID NO: 20, and an HCDR3 with an amino acid sequence as shown in SEQ ID NO: 21; and the light chain variable region of the anti-TIGIT immunoglobulin comprises an LCDR1 with an amino acid sequence as shown in SEQ ID NO: 22, an LCDR2 with an amino acid sequence as shown in SEQ ID NO: 23, and an LCDR3 with an amino acid sequence as shown in SEQ ID NO: 24.
[0036] In some embodiments of the present invention, the bispecific antibody, wherein
[0037] The amino acid sequence of the heavy chain variable region of the anti-PVRIG immunoglobulin or anti-PVRIG single-chain antibody is shown in SEQ ID NO: 5; and
[0038] The amino acid sequence of the light chain variable region of the anti-PVRIG immunoglobulin or anti-PVRIG single-chain antibody is shown in SEQ ID NO: 4;
[0039] Preferably, the glycine at position 44 of the heavy chain variable region of the anti-PVRIG immunoglobulin or anti-PVRIG single-chain antibody is replaced by cysteine, and the glycine at position 100 of the light chain variable region of the anti-PVRIG immunoglobulin or anti-PVRIG single-chain antibody is replaced by cysteine.
[0040] In some embodiments of the present invention, the bispecific antibody, wherein
[0041] The amino acid sequence of the heavy chain variable region of the anti-TIGIT immunoglobulin or anti-TIGIT single-chain antibody is shown in SEQ ID NO: 1; and the amino acid sequence of the light chain variable region of the anti-TIGIT immunoglobulin or anti-TIGIT single-chain antibody is shown in SEQ ID NO: 2;
[0042] or,
[0043] The amino acid sequence of the heavy chain variable region of the anti-TIGIT immunoglobulin or anti-TIGIT single-chain antibody is shown in SEQ ID NO: 3; and the amino acid sequence of the light chain variable region of the anti-TIGIT immunoglobulin or anti-TIGIT single-chain antibody is shown in SEQ ID NO: 4;
[0044] Preferably, the glycine at position 44 of the heavy chain variable region of the anti-TIGIT immunoglobulin or anti-TIGIT single-chain antibody is replaced with cysteine, and the glycine at position 100 of the light chain variable region of the anti-TIGIT immunoglobulin or anti-TIGIT single-chain antibody is replaced with cysteine.
[0045] In some embodiments of the present invention, the bispecific antibody, wherein the first protein functional region and the second protein functional region are directly connected or connected through a connecting fragment;
[0046] Preferably, the linker fragment is (GGGGS)m, where m is a positive integer, such as 1, 2, 3, 4, 5 or 6;
[0047] Preferably, the amino acid sequence of the connecting fragment is shown in SEQ ID NO:6.
[0048] In some embodiments of the present invention, in the bispecific antibody, the first protein functional region and the second protein functional region are independently 1, 2 or more.
[0049] In some embodiments of the present invention, the bispecific antibody, wherein:
[0050] The anti-TIGIT single-chain antibody (two molecules) is respectively connected to the C-termini of the two heavy chains of the anti-PVRIG immunoglobulin; or
[0051] The anti-PVRIG single-chain antibody (two molecules) is respectively connected to the C-termini of the two heavy chains of the anti-TIGIT immunoglobulin.
[0052] In some embodiments of the present invention, the bispecific antibody, wherein
[0053] The constant region of the anti-PVRIG immunoglobulin or anti-TIGIT immunoglobulin is derived from a human antibody;
[0054] Preferably, the constant region is independently selected from the constant region of human IgG1, IgG2, IgG3 or IgG4.
[0055] In some embodiments of the present invention, the bispecific antibody, wherein
[0056] The heavy chain constant region of the anti-PVRIG immunoglobulin or anti-TIGIT immunoglobulin is human Ig gamma-1 chain C region or human Ig gamma-4 chain C region, and the light chain constant region thereof is human Ig kappa chain C region;
[0057] Preferably, the heavy chain constant region of the anti-PVRIG immunoglobulin and anti-TIGIT immunoglobulin further comprises L234A mutation and L235A mutation (abbreviated as LALA) according to the EU numbering system.
[0058] In the present invention, unless otherwise specified, the letters before the site represent the amino acid before mutation, and the letters after the site represent the amino acid after mutation.
[0059] In some embodiments of the present invention, the bispecific antibody is a dimer or tetramer of two peptide chains with amino acid sequences as shown in SEQ ID NO: 7 and SEQ ID NO: 8, or a dimer or tetramer of two peptide chains with amino acid sequences as shown in SEQ ID NO: 9 and SEQ ID NO: 10.
[0060] Another aspect of the present invention relates to an isolated nucleic acid molecule encoding the bispecific antibody of any one of the present invention.
[0061] Yet another aspect of the present invention relates to a vector comprising the isolated nucleic acid molecule of the present invention.
[0062] Yet another aspect of the present invention relates to a host cell comprising the isolated nucleic acid molecule of the present invention, or the vector of the present invention.
[0063] Another aspect of the present invention relates to a conjugate comprising a bispecific antibody and a conjugated moiety, wherein the bispecific antibody is the bispecific antibody described in any one of the present invention, and the conjugated moiety is a detectable label; preferably, the conjugated moiety is a radioactive isotope, a fluorescent substance, a colored substance or an enzyme.
[0064] Another aspect of the present invention relates to a kit comprising the bispecific antibody according to any one of the present invention, or the conjugate according to the present invention;
[0065] Preferably, the kit further comprises a second antibody capable of specifically binding to the bispecific antibody; optionally, the second antibody further comprises a detectable label, such as a radioisotope, a fluorescent substance, a colored substance or an enzyme.
[0066] Another aspect of the present invention relates to a pharmaceutical composition comprising the bispecific antibody according to any one of the present invention, and one or more pharmaceutically acceptable excipients;
[0067] Preferably, the pharmaceutical composition further comprises at least one anti-PD-1 antibody;
[0068] Preferably, the molar ratio of the bispecific antibody to the anti-PD-1 antibody is (1:5) to (5:1), for example, 1:5, 1:4, 1:3, 1:2, 1:1, 2:1, 3:1, 4:1 or 5:1; more preferably 1:1.
[0069] In some embodiments of the present invention, the pharmaceutical composition, wherein the anti-PD-1 antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises HCDR1 to HCDR3, and the light chain variable region comprises LCDR1 to LCDR3, wherein:
[0070] The amino acid sequence of HCDR1 is shown in SEQ ID NO:36, the amino acid sequence of HCDR2 is shown in SEQ ID NO:37, the amino acid sequence of HCDR3 is shown in SEQ ID NO:38, the amino acid sequence of LCDR1 is shown in SEQ ID NO:39, the amino acid sequence of LCDR2 is shown in SEQ ID NO:40, and the amino acid sequence of LCDR3 is shown in SEQ ID NO:41;
[0071] Preferably, the amino acid sequence of the heavy chain variable region of the anti-PD-1 antibody is shown in SEQ ID NO: 34, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 35.
[0072] In one or more embodiments of the present invention, the pharmaceutical composition, wherein the unit dose of the pharmaceutical composition, calculated according to the mass of the bispecific antibody therein, is 100 mg-1000 mg, 200 mg-800 mg, 200 mg-500 mg, 300 mg-600 mg, 400 mg-500 mg or 450 mg.
[0073] Another aspect of the present invention relates to a combination product comprising a first product and a second product in separate packages, wherein:
[0074] The first product comprises the bispecific antibody according to any one of the present invention;
[0075] The second product comprises at least one anti-PD-1 antibody;
[0076] Preferably, the first product and the second product further independently contain one or more pharmaceutically acceptable excipients;
[0077] Preferably, the combination product further comprises product instructions.
[0078] In some embodiments of the present invention, the combination product, wherein the molar ratio of the bispecific antibody to the anti-PD-1 antibody is (1:5) to (5:1), for example, 1:5, 1:4, 1:3, 1:2, 1:1, 2:1, 3:1, 4:1 or 5:1; more preferably 1:1.
[0079] In some embodiments of the present invention, the combination product, wherein the anti-PD-1 antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises HCDR1 to HCDR3, and the light chain variable region comprises LCDR1 to LCDR3, wherein:
[0080] The amino acid sequence of HCDR1 is shown in SEQ ID NO:36, the amino acid sequence of HCDR2 is shown in SEQ ID NO:37, the amino acid sequence of HCDR3 is shown in SEQ ID NO:38, the amino acid sequence of LCDR1 is shown in SEQ ID NO:39, the amino acid sequence of LCDR2 is shown in SEQ ID NO:40, and the amino acid sequence of LCDR3 is shown in SEQ ID NO:41;
[0081] Preferably, the amino acid sequence of the heavy chain variable region of the anti-PD-1 antibody is shown in SEQ ID NO: 34, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 35.
[0082] Another aspect of the present invention relates to use of the bispecific antibody or conjugate of any one of the present invention in the preparation of a medicament for treating or preventing tumors;
[0083] Preferably, the tumor is selected from one or more of colon cancer, melanoma, lung cancer, kidney cancer, endometrial cancer, breast cancer, skin cancer, ovarian cancer, gastric cancer, head and neck cancer, liver cancer, brain tumor, urothelial cancer, bone tumor, bile duct cancer, rectal cancer, pancreatic cancer, cervical tumor, multiple myeloma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, B lymphocytic neoplasm, plasma cell cancer, prostate cancer and testicular cancer;
[0084] Preferably, the lung cancer is non-small cell lung cancer or small cell lung cancer.
[0085] The bispecific antibody, conjugate or pharmaceutical composition according to any one of the present invention, for treating or preventing tumors;
[0086] Preferably, the tumor is selected from one or more of colon cancer, melanoma, lung cancer, kidney cancer, endometrial cancer, breast cancer, skin cancer, ovarian cancer, gastric cancer, head and neck cancer, liver cancer, brain tumor, urothelial cancer, bone tumor, bile duct cancer, rectal cancer, pancreatic cancer, cervical tumor, multiple myeloma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, B lymphocytic neoplasm, plasma cell cancer, prostate cancer and testicular cancer;
[0087] Preferably, the lung cancer is non-small cell lung cancer or small cell lung cancer.
[0088] Another aspect of the present invention relates to a method for treating or preventing tumors, comprising the step of administering to a subject in need thereof an effective amount of the bispecific antibody, conjugate, or pharmaceutical composition of any one of the present invention;
[0089] Preferably, the tumor is selected from one or more of colon cancer, melanoma, lung cancer, kidney cancer, endometrial cancer, breast cancer, skin cancer, ovarian cancer, gastric cancer, head and neck cancer, liver cancer, brain tumor, urothelial cancer, bone tumor, bile duct cancer, rectal cancer, pancreatic cancer, cervical tumor, multiple myeloma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, B lymphocytic neoplasm, plasma cell cancer, prostate cancer and testicular cancer;
[0090] Preferably, the lung cancer is non-small cell lung cancer or small cell lung cancer.
[0091] In one or more embodiments of the present invention, the method, wherein,
[0092] The single dosage of the bispecific antibody is 0.1-100 mg per kilogram of body weight, preferably 1-10 mg (e.g., 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, or 10 mg); alternatively, the single dosage of the bispecific antibody is 10-1000 mg per subject (e.g., about 100 mg, about 150 mg, about 200 mg, about 250 mg, about 300 mg, about 350 mg, about 400 mg, about 450 mg, about 500 mg, about 600 mg, about 700 mg, about 800 mg, about 900 mg, or about 1000 mg), preferably 50-500 mg, 100-400 mg, 150-300 mg, 150-250 mg, or 200 mg;
[0093] Preferably, the drug is administered once every 3 days, 4 days, 5 days, 6 days, 10 days, 1 week, 2 weeks or 3 weeks;
[0094] Preferably, the administration is by intravenous drip or intravenous injection.
[0095] In some embodiments, the bispecific antibody is administered in a 2-week (14-day) or 3-week (21-day) cycle, preferably with the anti-PVRIG antibody administered intravenously on the first day (D1) of each cycle. For example, the bispecific antibody is administered once every two weeks (q2w) or once every three weeks (q3w).
[0096] Unless otherwise indicated, scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. Furthermore, the laboratory procedures for cell culture, molecular genetics, nucleic acid chemistry, and immunology used herein are conventional procedures widely used in the relevant fields. To facilitate a better understanding of the present invention, definitions and explanations of relevant terms are provided below.
[0097] As used herein, reference to the amino acid sequence of PVRIG (NCBI GenBank ID: NP_076975.2) includes the full-length or extracellular fragments of the PVRIG protein; it also includes fusion proteins of PVRIG, such as fragments fused to the Fc protein fragment of mouse or human IgG (mFc or hFc). However, those skilled in the art will appreciate that mutations or variations (including but not limited to substitutions, deletions, and / or additions) can occur naturally or be artificially introduced into the amino acid sequence of the PVRIG protein without affecting its biological function. Therefore, in the present invention, the term "PVRIG protein" or "PVRIG" should include all such sequences, including the sequence shown and its natural or artificial variants. Furthermore, when describing a sequence fragment of the PVRIG protein, it includes not only the sequence fragment, but also the corresponding sequence fragments in its natural or artificial variants.
[0098] As used herein, when referring to the amino acid sequence of TIGIT (NCBI GenBank ID: NP_776160.2), it includes the full length or functional fragments of the TIGIT protein; it also includes fusion proteins of TIGIT, such as fragments fused with the Fc protein fragment (mFc or hFc) of mouse or human IgG. However, those skilled in the art understand that mutations or variations (including but not limited to substitutions, deletions and / or additions) can be naturally generated or artificially introduced into the amino acid sequence of the TIGIT protein without affecting its biological function. Therefore, in the present invention, the term "TIGIT protein" or "TIGIT" should include all such sequences, including the sequence shown and its natural or artificial variants. Furthermore, when describing a sequence fragment of the TIGIT protein, it includes not only the sequence fragment, but also the corresponding sequence fragments in its natural or artificial variants.
[0099] As used herein, the term EC 50 It refers to the concentration for 50% of maximal effect, which is the concentration that can cause 50% of the maximum effect.
[0100] As used herein, the term "antibody" refers to an immunoglobulin molecule typically composed of two pairs of polypeptide chains, each pair having one "light" (L) chain and one "heavy" (H) chain. Antibody light chains can be classified as kappa and lambda light chains. Heavy chains can be classified as μ, δ, γ, α, or ε, and define the antibody's isotype as IgM, IgD, IgG, IgA, and IgE, respectively. Within the light and heavy chains, the variable and constant regions are connected by a "J" region of about 12 or more amino acids, and the heavy chain also contains a "D" region of about 3 or more amino acids. Each heavy chain consists of a heavy chain variable region (V H ) and heavy chain constant region (C H ). The heavy chain constant region consists of three domains (C H1 、C H2 and C H3 Each light chain consists of a light chain variable region (V L ) and the light chain constant region (C L ). The light chain constant region consists of a domain C L The constant region of the antibody mediates the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (C1q) of the classical complement system. H and V L The V domains can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDRs), interspersed with regions that are more conserved, termed framework regions (FRs). Hand V L It consists of three CDRs and four FRs arranged from amino terminus to carboxyl terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variable region (V H and V L ) form antigen-binding sites, respectively. The assignment of amino acids to each region or domain follows the Kabat Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda Md (1987 and 1991)), or Chothia & Lesk J. Mol. Biol. 1987; 196: 901-917; Chothia et al. Nature 1989; 342: 878-883 or the IMGT numbering system, as defined by Ehrenmann, Francois, Quentin Kaas, and Marie-Paule Lefranc. "IMGT / 3Dstructure-DB and IMGT / DomainGapAlign: a database and a tool for immunoglobulins or antibodies, T cell receptors, MHC, IgSF and MhcSF." Nucleic acids research 2009; 38(suppl_1): D301-D307. The term "antibody" is not limited to any particular method for producing the antibody. For example, it includes, in particular, recombinant antibodies, monoclonal antibodies and polyclonal antibodies.The antibody can be an antibody of different isotypes, for example, IgG (e.g., IgG1, IgG2, IgG3 or IgG4 subtype), IgA1, IgA2, IgD, IgE or IgM antibody.
[0101] As used herein, the term "antigen-binding fragment" of an antibody refers to a polypeptide comprising a fragment of a full-length antibody that retains the ability to specifically bind to the same antigen to which the full-length antibody is bound, and / or competes with the full-length antibody for specific binding to the antigen, and is also referred to as an "antigen-binding portion". See generally, Fundamental Immunology, Ch. 7 (Paul, W., ed., 2nd ed., Raven Press, NY (1989), which is incorporated herein by reference in its entirety for all purposes. Antigen-binding fragments of an antibody can be produced by recombinant DNA technology or by enzymatic or chemical cleavage of an intact antibody. In some cases, antigen-binding fragments include Fab, Fab', F(ab')2, Fd, Fv, dAb and complementary determining region (CDR) fragments, single-chain antibodies (e.g., scFv), chimeric antibodies, diabodies, and polypeptides comprising at least a portion of an antibody sufficient to confer specific antigen-binding ability to a polypeptide.
[0102] As used herein, the term "Fd fragment" means a fragment consisting of H and C H The term "Fv fragment" refers to an antibody fragment consisting of a V domain of a single arm of an antibody. L and V H The term "dAb fragment" refers to an antibody fragment consisting of a V H domains (Ward et al., Nature 341:544-546 (1989)); the term "Fab fragment" means an antibody fragment consisting of V L 、V H 、C L and C H The term "F(ab')2 fragment" refers to an antibody fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region.
[0103] In some cases, the antigen-binding fragment of an antibody is a single-chain antibody (e.g., scFv), in which V L and V H The domains are paired to form monovalent molecules through linkers that enable them to be produced as a single polypeptide chain (see, e.g., Bird et al., Science 242:423-426 (1988) and Huston et al., Proc. Natl. Acad. Sci. USA 85:5879-5883 (1988)). Such scFv molecules can have the general structure: NH2-V L -Connector-V H -COOH or NH2-V H -Connector-V L-COOH. Suitable prior art linkers consist of repeated GGGGS amino acid sequences or variants thereof. For example, a linker having the amino acid sequence (GGGGS)4 can be used, but variants thereof can also be used (Holliger et al. (1993), Proc. Natl. Acad. Sci. USA 90:6444-6448). Other linkers that can be used in the present invention are described by Alfthan et al. (1995), Protein Eng. 8:725-731, Choi et al. (2001), Eur. J. Immunol. 31:94-106, Hu et al. (1996), Cancer Res. 56:3055-3061, Kipriyanov et al. (1999), J. Mol. Biol. 293:41-56 and Roovers et al. (2001), Cancer Immunol.
[0104] In some cases, the antigen-binding fragment of an antibody is a diabody, i.e., a bivalent antibody in which V H and V L The domains are expressed on a single polypeptide chain, but with a linker that is too short to allow pairing between the two domains on the same chain, thereby forcing the domains to pair with the complementary domains of another chain and create two antigen-binding sites (see, e.g., Holliger P. et al., Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993), and Poljak RJ et al., Structure 2:1121-1123 (1994)).
[0105] In other cases, the antigen-binding fragment of an antibody is a "bispecific antibody", which refers to a conjugate formed by a first antibody (fragment) and a second antibody (fragment) or an antibody analog through a coupling arm, and the coupling method includes but is not limited to chemical reaction, gene fusion and enzymatic reaction. The antigen-binding fragment of an antibody can be a "multispecific antibody" including, for example: a trispecific antibody and a tetraspecific antibody, the former being an antibody with three different antigen-binding specificities, and the latter being an antibody with four different antigen-binding specificities. For example, a designed ankyrin repeat protein (DARPin) is linked to an IgG antibody, a scFv-Fc antibody fragment, or a combination thereof, such as CN104341529A. The anti-IL-17a fynomer is bound to an anti-IL-6R antibody, such as WO2015141862A1.
[0106] Antigen-binding fragments of antibodies (e.g., the above-mentioned antibody fragments) can be obtained from a given antibody (e.g., monoclonal antibodies ADI-56127, ADI-55796, and ADI-55812 provided herein) using conventional techniques known to those skilled in the art (e.g., recombinant DNA technology or enzymatic or chemical cleavage methods), and the antigen-binding fragments of antibodies can be screened for specificity in the same manner as for intact antibodies.
[0107] As used herein, the terms "monoclonal antibody" and "monoclonal antibody" refer to an antibody or an antibody fragment from a group of highly homologous antibody molecules, that is, a group of identical antibody molecules except for possible spontaneous natural mutations. Monoclonal antibodies have high specificity for a single epitope on an antigen. Polyclonal antibodies are relative to monoclonal antibodies and usually contain at least two or more different antibodies, and these different antibodies usually recognize different epitopes on the antigen. Monoclonal antibodies can usually be obtained using the hybridoma technology first reported by Kohler et al. ( G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity [J]. Nature, 1975; 256 (5517): 495), but it can also be obtained by using recombinant DNA technology (see, for example, US Patent 4,816,567).
[0108] As used herein, the term "humanized antibody" refers to an antibody or antibody fragment obtained by replacing all or part of the CDR region of a human immunoglobulin (recipient antibody) with the CDR region of a non-human antibody (donor antibody), wherein the donor antibody can be a non-human (e.g., mouse, rat, or rabbit) antibody with the desired specificity, affinity, or reactivity. In addition, some amino acid residues in the framework region (FR) of the recipient antibody can also be replaced with amino acid residues of the corresponding non-human antibody, or with amino acid residues of other antibodies, to further improve or optimize the performance of the antibody. For more details on humanized antibodies, see, for example, Jones et al., Nature 1986; 321: 522-525; Reichmann et al., Nature 1988; 332: 323-329; Presta, Curr. Op. Struct. Biol., 1992; 2: 593-596; and Clark M. Antibody humanization: a case of the 'Emperor's new clothes'? [J]. Immunol. Today, 2000; 21(8): 397-402.
[0109] As used herein, the term "isolated" or "isolated" refers to something that is obtained artificially from its natural state. If a substance or component is "isolated" in nature, it may be that its natural environment has been changed, or that the substance has been separated from its natural environment, or both. For example, a certain unisolated polynucleotide or polypeptide naturally exists in a living animal, and a highly pure identical polynucleotide or polypeptide isolated from this natural state is called isolated. The term "isolated" or "isolated" does not exclude the presence of artificial or synthetic substances, nor does it exclude the presence of other impure substances that do not affect the activity of the substance.
[0110] As used herein, the term "vector" refers to a nucleic acid delivery vehicle into which a polynucleotide can be inserted. When a vector is capable of expressing a protein encoded by the inserted polynucleotide, it is referred to as an expression vector. A vector can be introduced into a host cell via transformation, transduction, or transfection, allowing the genetic material it carries to be expressed in the host cell. Vectors are well known to those skilled in the art and include, but are not limited to, plasmids; phagemids; cosmids; artificial chromosomes, such as yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), or P1-derived artificial chromosomes (PACs); bacteriophages, such as lambda phage or M13 phage, and animal viruses. Animal viruses that can be used as vectors include, but are not limited to, retroviruses (including lentiviruses), adenoviruses, adeno-associated viruses, herpes viruses (such as herpes simplex virus), poxviruses, baculoviruses, papillomaviruses, and papillomas (such as SV40). A vector can contain a variety of elements that control expression, including, but not limited to, promoter sequences, transcription initiation sequences, enhancer sequences, selection elements, and reporter genes. Additionally, a vector may contain an origin of replication.
[0111] As used herein, the term "host cell" refers to a cell that can be used to introduce a vector, including but not limited to prokaryotic cells such as Escherichia coli or Bacillus subtilis, fungal cells such as yeast cells or Aspergillus, insect cells such as S2 Drosophila cells or Sf9, or animal cells such as fibroblasts, CHO cells, COS cells, NSO cells, HeLa cells, GS cells, BHK cells, HEK 293 cells or human cells.
[0112] As used herein, the term "specific binding" refers to a non-random binding reaction between two molecules, such as an antibody and its antigen. In certain embodiments, an antibody that specifically binds to an antigen (or has specificity for an antigen) means that the antibody binds to the antigen with a specificity of less than about 10 -5 M, for example, less than about 10 -6 M, 10 -7 M, 10 -8 M, 10 -9 M or 10 -10 Affinity of M or less (K D ) binds to the antigen.
[0113] As used herein, the term "K D " refers to the dissociation equilibrium constant of a specific antibody-antigen interaction, which is used to describe the binding affinity between the antibody and the antigen. The smaller the equilibrium dissociation constant, the tighter the antibody-antigen binding and the higher the affinity between the antibody and the antigen. Generally, antibodies bind with a dissociation equilibrium constant of less than about 10 -5 M, for example, less than about 10 -6M, 10 -7 M, 10 -8 M, 10 -9 M or 10 -10 M or less dissociation equilibrium constant (K D ) binding antigen (eg, TIGIT protein). K can be determined using methods known to those skilled in the art. D , for example, using the Fortebio molecular interaction instrument.
[0114] As used herein, the terms "monoclonal antibody" and "monoclonal antibody" have the same meaning and are used interchangeably; the terms "polyclonal antibody" and "polyclonal antibody" have the same meaning and are used interchangeably; the terms "polypeptide" and "protein" have the same meaning and are used interchangeably. Furthermore, in the present invention, amino acids are generally represented by single-letter and three-letter abbreviations known in the art. For example, alanine can be represented by A or Ala.
[0115] As used herein, the term "pharmaceutically acceptable excipient" refers to a carrier and / or excipient that is pharmacologically and / or physiologically compatible with the subject and the active ingredient, which is well known in the art (see, for example, Remington's Pharmaceutical Sciences. Edited by Gennaro AR, 19th ed. Pennsylvania: Mack Publishing Company, 1995), and includes, but is not limited to, pH adjusters, surfactants, adjuvants, and ionic strength enhancers. For example, pH adjusters include, but are not limited to, phosphate buffers; surfactants include, but are not limited to, cationic, anionic, or nonionic surfactants, such as Tween-80; and ionic strength enhancers include, but are not limited to, sodium chloride.
[0116] As used herein, the term "effective amount" refers to an amount sufficient to achieve or at least partially achieve a desired effect. For example, an effective amount for preventing a disease (e.g., a tumor) refers to an amount sufficient to prevent, inhibit, or delay the occurrence of a disease (e.g., a tumor); an effective amount for treating a disease refers to an amount sufficient to cure or at least partially inhibit the disease and its complications in a patient already suffering from the disease.
[0117] As used herein, the terms "hybridoma" and "hybridoma cell line" are used interchangeably, and the terms "hybridoma" and "hybridoma cell line" also include subclones and progeny cells of the hybridoma when referring to them.
[0118] In the present invention, unless otherwise specified, the "first" (e.g., the first product) and "second" (e.g., the second product) are for reference distinction or clarity of expression, and do not have a typical order meaning.
[0119] Advantageous Effects of the Invention
[0120] The present invention achieves one or more of the following technical effects (1) to (4):
[0121] (1) The bispecific antibody of the present invention can bind to TIGIT and PVRIG with high affinity.
[0122] (2) The bispecific antibody of the present invention is likely to have a synergistic effect with the anti-PD-1 antibody or anti-PD-L1 antibody.
[0123] (3) The antibodies of the present invention can effectively treat and / or prevent tumors, such as colon cancer, melanoma, lung cancer, kidney cancer, endometrial cancer, breast cancer, skin cancer, ovarian cancer, gastric cancer, head and neck cancer, liver cancer, brain tumors, urothelial cancer, bone tumors, bile duct cancer, rectal cancer, pancreatic cancer, cervical tumors, multiple myeloma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, B lymphocytic neoplasm, plasma cell carcinoma, prostate cancer and testicular cancer.
[0124] (4) The bispecific antibody of the present invention has lower toxic side effects. BRIEF DESCRIPTION OF THE DRAWINGS
[0125] 1A to 1C are schematic structural diagrams of the bispecific antibodies of the present invention.
[0126] FIG2 : Binding curve of the bispecific antibody of the present invention to human TIGIT overexpressed in CHO cells.
[0127] FIG3 : Binding curve of the bispecific antibody of the present invention to cynomolgus monkey TIGIT overexpressed in CHO cells.
[0128] FIG4 : Binding curve of the bispecific antibody of the present invention to mouse TIGIT overexpressed in CHO cells.
[0129] FIG5 is a graph showing that the bispecific antibodies of the present invention block the binding of human CD155 to human TIGIT overexpressed on CHO cells.
[0130] FIG6 is a graph showing that the bispecific antibodies of the present invention blocked the binding of mouse CD155 to mouse TIGIT overexpressed on CHO cells.
[0131] FIG7 : Binding curve of the bispecific antibody of the present invention to human PVRIG overexpressed in CHO cells.
[0132] FIG8 : Binding curve of the bispecific antibody of the present invention to cynomolgus monkey PVRIG overexpressed in CHO cells.
[0133] FIG9 : Binding curve of the bispecific antibody of the present invention to mouse PVRIG overexpressed in CHO cells.
[0134] FIG10 is a graph showing that the bispecific antibodies of the present invention block the binding of human PVRIG to human CD112 overexpressed on CHO cells.
[0135] FIG11 is a graph showing that the bispecific antibodies of the present invention block the binding of mouse CD112 to mouse PVRIG protein.
[0136] Figure 12 is a graph showing that the bispecific antibodies of the present invention simultaneously bind to human PVRIG and human TIGIT proteins.
[0137] FIG13 is a graph showing that the bispecific antibodies of the present invention block the TIGIT / CD155 and PVRIG / CD112 signaling pathways.
[0138] Figures 14A to 14B are graphs showing the bispecific antibodies of the present invention combined with anti-PD-1 / L1 monoclonal antibodies blocking TIGIT / CD155, PVRIG / CD112, and PD-1 / PD-L1 signaling pathways.
[0139] FIG15 is a graph showing the pharmacodynamic curve of the bispecific antibody of the present invention in the B-NDG mouse model inoculated with A375 and human PBMC.
[0140] Figures 16A to 16B show the pharmacodynamic curves of the bispecific antibody of the present invention combined with anti-PD-1 monoclonal antibody in the B-NDG mouse model inoculated with A375 and human PBMCs.
[0141] FIG17 shows the half-life curve of the bispecific antibody of the present invention in mice.
[0142] FIG18 : Binding activity curve of the anti-TIGIT antibody of the present invention to human TIGIT overexpressed in CHO cells.
[0143] FIG19 : Binding activity curve of the anti-TIGIT antibody of the present invention to cynomolgus monkey TIGIT overexpressed in CHO cells.
[0144] FIG20 : Binding activity curve of the anti-TIGIT antibody of the present invention to mouse TIGIT overexpressed in CHO cells.
[0145] Figure 21: Blocking activity curve of the anti-TIGIT antibodies of the present invention in blocking the binding of human CD155 to human TIGIT overexpressed on CHO cells.
[0146] FIG22 : Blocking activity curve of the anti-TIGIT antibodies of the present invention in blocking the binding of mouse CD155 to mouse TIGIT overexpressed on CHO cells.
[0147] Figure 23: Binding activity curve of the anti-TIGIT antibody of the present invention to TIGIT on activated human primary T cells.
[0148] FIG24 shows the binding activity curve of the anti-PVRIG antibody of the present invention to human PVRIG overexpressed in CHO cells.
[0149] FIG25 : Binding activity curve of the anti-PVRIG antibody of the present invention to cynomolgus monkey PVRIG overexpressed in CHO cells.
[0150] FIG26 shows the binding activity curve of the anti-PVRIG antibody of the present invention to mouse PVRIG overexpressed in CHO cells.
[0151] FIG27 : Blocking activity curve of the anti-PVRIG antibodies of the present invention in blocking the binding of human PVRIG to human CD112 overexpressed on CHO cells.
[0152] FIG28 is a graph showing that anti-PVRIG antibodies block the binding of mouse CD112 to mouse PVRIG protein.
[0153] FIG29 : Binding curve of anti-PVRIG antibodies to PVRIG on activated human primary T cells.
[0154] FIG30 : Pharmacodynamics of anti-PVRIG antibody in NDG mouse model inoculated with A375 and human PBMC. DETAILED DESCRIPTION
[0155] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are intended to illustrate the present invention only and are not intended to limit the scope of the present invention. The experimental methods in the following examples, for which specific conditions are not specified, are generally performed under conventional conditions, such as those described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or according to the conditions recommended by the manufacturer. Unless otherwise stated, percentages and parts are by weight.
[0156] Antibody Atezolizumab: anti-PD-L1 monoclonal antibody, trade name Tecentriq, Roche.
[0157] Antibody Pembrolizumab: anti-PD-1 monoclonal antibody, trade name Keytruda, Merck.
[0158] The following control antibodies were expressed and purified from HEK293 cells:
[0159] COM701 is an anti-human PVRIG antibody from Compugen, expressed in HEK293 cells. Its light chain variable region sequence and heavy chain variable region sequence are consistent with SEQ ID NO: 1372 and SEQ ID NO: 1380 in U.S. Patent No. 10227408B2.
[0160] Mab46 is an anti-human PVRIG antibody from Surface Oncology expressed in HEK293 cells. The sequences of its light chain variable region and heavy chain variable region are consistent with SEQ ID NO: 912 and SEQ ID NO: 918 in U.S. Patent Publication No. US20200040081A1.
[0161] Tiragolumab is an anti-human TIGIT antibody from Genentech expressed in HEK293 cells. Its light chain and heavy chain sequences are derived from WHO Drug Information, Vol. 31, No. 2, 2017, Proposed INN: List 117, CAS No.: 1918185-84-8.
[0162] Example 1: Design and preparation of anti-TIGIT-anti-PVRIG bispecific antibodies
[0163] In this example, the scFv of the anti-PVRIG monoclonal antibody ADI-56127 was connected in series to the C-terminus of the heavy chain of the anti-TIGIT monoclonal antibody ADI-55796 via a GGGGSGGGGSG (SEQ ID NO: 44) (other linkers such as GGGGSGGGGS, SEQ ID NO: 6 may also be used) linker ( FIG1A ). The scFv of the anti-TIGIT monoclonal antibody ADI-55796 was connected in series to the C-terminus of the heavy chain of the anti-PVRIG monoclonal antibody ADI-56127 via a GGGGSGGGGSG (other linkers such as GGGGSGGGGS may also be used) linker ( FIG1B ). The heavy chain of the anti-TIGIT monoclonal antibody ADI-55812 (with the CH3 region mutated to form a “knob” structure) and the heavy chain of the anti-PVRIG monoclonal antibody ADI-56127 (with the CH3 region mutated to form a “hole” structure) were connected in series to form a “knob into The two molecules were combined into a "1+1" molecular structure in a "hole" manner (Figure 1C), forming three anti-TIGIT / PVRIG bispecific antibodies with different structures, named TP-007-008, TP-003-009, and TP-001-002-003, respectively. Their schematic structures are shown in Figures 1A to 1C. The scFv of the anti-TIGIT antibody and the scFv of the anti-PVRIG antibody both use a "VH-linker-VL" connection method, and the flexible peptide linker between VH and VL is GGGGSGGGGSGGGGSGGGGSG (SEQ ID NO: 45) (other flexible peptide linkers such as GGGGSGGGGSGGGGSGGGGS, SEQ ID NO: 46 can also be used), and the glycine at position 44 of the heavy chain variable region and position 100 of the light chain variable region of the anti-TIGIT monoclonal antibody ADI-55796 and the anti-PVRIG monoclonal antibody ADI-56127 are mutated to cysteine to enhance the stability of the scFv. All three bispecific antibodies use the human IgG1 subtype. The sequences of the anti-TIGIT monoclonal antibodies ADI-55796, ADI-55812 and anti-PVRIG monoclonal antibodies ADI-56127 and the bispecific antibodies formed are shown in Table 1 below.
[0164] Table 1: Antibody sequences of anti-TIGIT-anti-PVRIG dual antibodies and corresponding single antibodies
[0165] Molecular cloning techniques were used to construct the antibody peptide sequences into pcDNA3.1 expression frames. Using chemical transfection, the pcDNA3.1 vector carrying peptide chains #1 and #2 of the anti-TIGIT-anti-PVRIG bispecific antibody TP-007-008 was transformed into HEK293 cells to produce the TP-007-008 bispecific antibody. The pcDNA3.1 vector carrying peptide chains #1 and #2 of the anti-TIGIT-anti-PVRIG bispecific antibody TP-003-009 was transformed into HEK293 cells to produce the TP-003-009 bispecific antibody. The pcDNA3.1 vector carrying peptide chains #1, #2, and #3 of the anti-TIGIT-anti-PVRIG bispecific antibody TP-001-002-003 was transformed into HEK293 cells to produce the TP-001-002-003 bispecific antibody. After 5 days of cell culture, the supernatant was collected and the target protein was purified using protein A magnetic beads (purchased from GenScript). The magnetic beads were resuspended in an appropriate volume of binding buffer (PBS + 0.1% Tween 20, pH 7.4) (1-4 times the volume of the magnetic beads) and added to the sample to be purified. Incubate at room temperature for 1 hour with gentle shaking. The sample was placed on a magnetic stand (purchased from Beaver), the supernatant was discarded, and the magnetic beads were washed 3 times with binding buffer. Elution buffer (0.1M sodium citrate, pH 3.2) was added according to 3-5 times the volume of the magnetic beads and shaken at room temperature for 5-10 minutes. The beads were returned to the magnetic stand, the elution buffer was collected, and the mixture was transferred to a collection tube with neutralization buffer (1M Tris, pH 8.54) and mixed. Purified bispecific antibodies TP-007-008, TP-003-009, and TP-001-002-003 were obtained, ultrafiltered and replaced into PBS, and the molecular weight was confirmed by LC-MS for subsequent in vitro and in vivo activity detection.
[0166] Example 2: Antibody affinity detection
[0167] The binding dissociation constants (K) of the three bispecific antibodies obtained in Example 1 and their corresponding three monoclonal antibody molecules, Anti-TIGIT monoclonal antibody ADI-55796, Anti-TIGIT monoclonal antibody ADI-55812, and Anti-PVRIG monoclonal antibody ADI-56127, binding to human and cynomolgus monkey TIGIT and PVRIG proteins were determined by using biofilm optical interferometry (ForteBio). DThe Fortebio affinity assay was performed according to the existing method (Este, P et al. High throughput solution-based measurement of antibody-antigen affinity and epitope binning. Mabs, 2013. 5(2): p. 270-8). The amino acid sequences of the extracellular segments of human TIGIT and cynomolgus monkey TIGIT, and the amino acid sequences of the extracellular segments of human PVRIG and cynomolgus monkey PVRIG are shown in Table 1 above.
[0168] The specific operations are as follows:
[0169] Monovalent affinity measurements of antibodies for human and cynomolgus macaque TIGIT-his proteins, as well as human PVRIG-his proteins, were performed by equilibrating the sensor offline in assay buffer for 20 minutes, followed by an online measurement for 120 seconds to establish a baseline. The intact antibody was then loaded onto the AHQ sensor to a thickness of 1 nm for affinity measurement. The loaded sensor was incubated with 100 nM target antigen until plateau phase, and then the sensor was transferred to assay buffer for at least 2 minutes for dissociation rate measurement. Kinetic analysis was performed using a 1:1 binding model.
[0170] To measure the bivalent affinity of the antibody for the cynomolgus monkey PVRIG-Fc protein, the sensor was equilibrated offline in assay buffer for 20 minutes, followed by an online assay for 120 seconds to establish a baseline. The intact antibody was then loaded onto the AHQ sensor to a thickness of 1 nm for affinity measurement. The loaded sensor was then incubated with a high concentration of an irrelevant intact antibody for 10 minutes to saturate the Fc binding sites on the AHQ sensor. The blocked sensor was then incubated with 100 nM target antigen until plateau phase was reached, and the sensor was then transferred to assay buffer for at least 2 minutes for dissociation rate measurement. Kinetic analysis was performed using a 1:1 binding model.
[0171] Bispecific antibodies and their corresponding monoclonal antibody molecules bind to the K of human, cynomolgus monkey TIGIT and PVRIG D The values are shown in Table 2 below.
[0172] Table 2: K values of anti-TIGIT-anti-PVRIG dual antibodies and corresponding single antibodies D value Note: "ND": Not Detected. "WB": Weakly Binded.
[0173] The results showed that the monovalent affinity of the anti-TIGIT / PVRIG bispecific antibodies TP-007-008 and TP-003-009 for binding to human TIGIT and cynomolgus macaque TIGIT antigens was similar to that of their single-terminal antibody molecule ADI-55796; the monovalent affinity of the anti-TIGIT / PVRIG bispecific antibody TP-001-002-003 for binding to human TIGIT antigen was similar to that of their single-terminal antibody molecule ADI-55812; The monovalent affinity of the bispecific antibodies TP-007-008, TP-003-009, and TP-001-002-003 for binding to human PVRIG antigen is similar to that of its single-terminal antibody molecule ADI-56127; the bispecific affinity of the anti-TIGIT / PVRIG bispecific antibodies TP-007-008, TP-003-009, and TP-001-002-003 for binding to crab-eating macaque PVRIG antigen is similar to that of its single-terminal antibody molecule ADI-56127.
[0174] Example 3: Binding and blocking activities of anti-TIGIT-anti-PVRIG bispecific antibodies against CHO cells overexpressing human / cynomolgus monkey / mouse TIGIT
[0175] 3.1 Flow cytometry was used to detect the binding activity of the anti-TIGIT-anti-PVRIG bispecific antibody to human / cynomolgus monkey / mouse TIGIT overexpressed in CHO cells.
[0176] Specifically, CHO-S cells overexpressing human TIGIT (CHO-huTIGIT cells), CHO-S cells overexpressing crab-eating macaque TIGIT (CHO-cynoTIGIT cells), and CHO-S cells overexpressing mouse TIGIT (CHO-muTIGIT cells) were produced by pressure screening by transfecting the pCHO1.0 vector (purchased from Invitrogen) cloned into MCS with human TIGIT, cynomolgus macaque TIGIT, and mouse TIGIT cDNA. The expanded overexpressing cells were adjusted to an appropriate cell density and added to a 96-well flow plate. After centrifugation, gradient dilutions of the test samples were added and incubated at 4°C for 30 minutes. Wash twice with PBS, add the corresponding fluorescent secondary antibody diluted to the appropriate concentration, and incubate at 4°C for 30 minutes. Wash twice with PBS, resuspend the cells in PBS, detect on a CytoFlex flow cytometer, and calculate the corresponding MFI. Graphpad software was used for graphical analysis to obtain EC 50 Numeric value.
[0177] The results are shown in Table 3 and Figures 2 to 4.
[0178] Table 3: Binding or blocking activity of anti-TIGIT-anti-PVRIG dual antibodies against TIGIT / CD155 Note: "NB" does not bind.
[0179] The results showed that the binding activity of the anti-TIGIT-anti-PVRIG bispecific antibody TP-007-008 of the present invention to human / cynomolgus monkey / mouse TIGIT overexpressed in CHO cells was similar to that of its TIGIT-terminal monoclonal antibody molecule ADI-55796.
[0180] 3.2 Based on flow cytometry detection, the anti-TIGIT-anti-PVRIG bispecific antibody was used to detect the binding blocking activity of human CD155 to human TIGIT overexpressed on CHO cells and the binding blocking activity of mouse CD155 to mouse TIGIT overexpressed on CHO cells.
[0181] Specifically, the cell density of the expanded cultured CHO-huTIGIT cells was adjusted to 2×10 6 Cells / mL, 100 μL / well added to a 96-well flow cytometry plate, centrifuged and set aside. Dilute the antibody to be tested with PBS, starting with 400 nM and making 3-fold dilutions for a total of 12 points. Add 60 μL / well of the diluted sample to the above 96-well flow cytometry plate with cells and incubate at 4°C for 30 minutes. Then, add 60 μL / well of human CD155 protein with Mouse IgG2a Fc Tag to a final concentration of 2 μg / mL and incubate at 4°C for 30 minutes. Wash twice with PBS, add 100 μL / well of APC goat anti-mouse IgG antibody diluted 100-fold with PBS and incubate at 4°C for 30 minutes. Wash twice with PBS, resuspend the cells in 100 μL / well of PBS, detect on the CytoFlex flow cytometer and calculate the corresponding MFI.
[0182] The cell density of the expanded CHO-muTIGIT cells was adjusted to 2×10 6 cells / mL, 100μL / well was added to a 96-well flow plate, centrifuged and set aside. The antibody to be tested was diluted with PBS, starting from 400nM and diluted 3 times for a total of 12 points. 60μL / well of the diluted sample was added to the above 96-well flow plate with cells and incubated at 4°C for 30 minutes. Then 60μL / well of mouse CD155 protein with Mouse IgG2a Fc Tag was added to a final concentration of 2μg / mL and incubated at 4°C for 30 minutes. Wash twice with PBS, add 100μL / well of APC goat anti-mouse IgG antibody diluted 100 times with PBS, and incubate at 4°C for 30 minutes. Wash twice with PBS, add 100μL / well of PBS to resuspend the cells, detect on the CytoFlex flow cytometer and calculate the corresponding MFI. Graphpad software was used for graphical analysis to obtain IC 50Numeric value.
[0183] The results are shown in Table 3 and Figures 5 to 6. The results showed that the anti-TIGIT-anti-PVRIG bispecific antibody TP-007-008 of the present invention had similar blocking activity on the binding of human CD155 to human TIGIT overexpressed on CHO cells and the binding of mouse CD155 to mouse TIGIT overexpressed on CHO cells as its TIGIT-terminal monoclonal antibody molecule ADI-55796.
[0184] Example 4: Binding and blocking activity of anti-TIGIT-anti-PVRIG bispecific antibodies against CHO cells overexpressing human / cynomolgus monkey / mouse PVRIG
[0185] 4.1 Flow cytometry was used to detect the binding activity of the anti-TIGIT-anti-PVRIG bispecific antibody to human / cynomolgus monkey / mouse PVRIG overexpressed in CHO cells.
[0186] Specifically, CHO-S cells overexpressing human PVRIG (CHO-huPVRIG cells), CHO-S cells overexpressing cynomolgus monkey PVRIG (CHO-cynoPVRIG cells), and CHO-S cells overexpressing mouse PVRIG (CHO-muPVRIG cells) were generated by pressure screening by transfecting human PVRIG, cynomolgus monkey PVRIG, and mouse PVRIG cloned into MCS. The expanded overexpressing cells were adjusted to an appropriate cell density and added to a 96-well flow plate. After centrifugation, the gradient diluted sample to be tested was added and incubated at 4°C for 30 minutes. Wash twice with PBS, add the corresponding fluorescent secondary antibody diluted to the appropriate concentration, and incubate at 4°C for 30 minutes. Wash twice with PBS, resuspend the cells in PBS, detect on a CytoFlex flow cytometer, and calculate the corresponding MFI. Graphpad software was used for graphical analysis to obtain EC 50 Numeric value.
[0187] The results are shown in Table 4 and Figures 7 to 9.
[0188] Table 4: Binding or blocking activity of anti-TIGIT-anti-PVRIG dual antibodies against PVRIG / CD112
[0189] The results showed that the binding activity of the anti-TIGIT-anti-PVRIG bispecific antibody TP-003-009 of the present invention to human / crab-eating macaque / mouse PVRIG overexpressed on CHO cells was similar to that of its PVRIG-terminal monoclonal antibody molecule ADI-56127; the binding activity of the anti-TIGIT-anti-PVRIG bispecific antibody TP-007-008 of the present invention to human PVRIG overexpressed on CHO cells was similar to that of its PVRIG-terminal monoclonal antibody molecule ADI-56127.
[0190] 4.2 The blocking activity of the anti-TIGIT-anti-PVRIG bispecific antibody on the binding of human PVRIG to human CD112 overexpressed on CHO cells was detected based on flow cytometry.
[0191] Specifically, CHO-S cells (CHO-huCD112 cells) overexpressing human CD112 were generated by pressure screening by transfecting the pCHO1.0 vector (purchased from Invitrogen) of human CD112 cloned into MCS. The purified test antibody was diluted with PBS, and 60 μL / well of the diluted sample was added to a 96-well flow plate. Then 1 μg / mL of human PVRIG protein with Mouse IgG2a Fc Tag was added to 60 μL / well, mixed, and incubated at 4°C for 30 minutes. The cell density of the expanded cultured CHO-huCD112 cells was adjusted to 2×10 6 cells / mL, 100 μL / well was added to a 96-well flow plate, and the supernatant was discarded after centrifugation. 100 μL / well was added to the above-mentioned co-incubated antibody-antigen mixture, and incubated at 4°C for 30 minutes. Washed twice with PBS, 100 μL / well was added to APC goat anti-Mouse IgG diluted 100 times with PBS, and incubated at 4°C for 30 minutes. Washed twice with PBS, 100 μL / well was added to PBS to resuspend the cells, and the cells were detected on a CytoFlex flow cytometer and the corresponding MFI was calculated. Graphpad software was used for graphical analysis to obtain IC 50 Numeric value.
[0192] The results are shown in Table 4 and Figure 10. The blocking activity of the anti-TIGIT-anti-PVRIG bispecific antibodies TP-007-008 and TP-003-009 of the present invention on the binding of human PVRIG to human CD112 overexpressed on CHO cells is similar to that of their PVRIG-terminal monoclonal antibody molecule ADI-56127.
[0193] 4.3 The blocking activity of anti-TIGIT-anti-PVRIG bispecific antibody on the binding of mouse PVRIG to mouse CD112 protein was detected based on enzyme-linked immunosorbent assay.
[0194] Specifically, mouse CD112-his protein was dissolved according to the manufacturer's instructions and diluted to 1 μg / mL in 1× ELISA coating buffer. 100 μL / well was coated onto a 96-well ELISA plate and incubated overnight at 4°C. The coating buffer was discarded, the plate was washed three times with 1× PBST, and then blocked with 200 μL / well of 5% BSA / PBS at room temperature for 2 hours. During the blocking period, the purified test antibody was serially diluted with 1% BSA / PBS to a final volume of 60 μL / well. Biotinylated mouse PVRIG protein with a mouse IgG2a Fc tag was then added at 60 μL / well, mixed, and incubated at room temperature for 1 hour. After blocking, the blocking buffer was discarded from the ELISA plate, and 100 μL / well of the antibody-antigen mixture was added, incubated at room temperature for 2 hours. The antibody-antigen mixture was discarded, the plate was washed three times with 1× PBST, and 100 μL / well of SA-HRP diluted in 1% BSA / PBS was added, incubated at room temperature for 1 hour. Discard the SA-HRP diluent, wash three times with 1×PBST, add 100 μL / well ELISA colorimetric solution and react at room temperature for 1-3 minutes, add 50 μL / well ELISA stop solution, and read the absorbance value at 450 nm. Use Graphpad software to plot the concentration-absorbance value binding curve and obtain the IC 50 Numeric value.
[0195] The results are shown in Table 4 and Figure 11. The blocking activity of the anti-TIGIT-anti-PVRIG bispecific antibody TP-003-009 of the present invention on the binding of mouse PVRIG to mouse CD112 protein is similar to that of its PVRIG-terminal monoclonal antibody molecule ADI-56127.
[0196] Example 5: Co-binding activity of anti-TIGIT-anti-PVRIG bispecific antibody to human TIGIT and human PVRIG
[0197] The co-binding activity of the anti-TIGIT-anti-PVRIG bispecific antibody of the present invention with human TIGIT and human PVRIG protein was detected based on enzyme-linked immunosorbent assay (ELISA).
[0198] Specifically, human PVRIG protein was dissolved according to the manufacturer's instructions and diluted to 1 μg / mL in 1× ELISA coating buffer. 100 μL / well was coated onto a 96-well ELISA plate and incubated overnight at 4°C. The coating buffer was discarded, the plate was washed three times with 1× PBST, and 200 μL / well was added to block with 5% BSA / PBS at room temperature for 2 hours. The blocking buffer was discarded, and 100 μL / well of a serial dilution of the test antibody in 1% BSA / PBS was added and incubated at room temperature for 2 hours. The antibody diluent was discarded, the plate was washed three times with 1× PBST, and 100 μL / well of biotin-labeled TIGIT protein diluted in 1% BSA / PBS was added to a final concentration of 1 μg / mL and incubated at room temperature for 1 hour. The antigen diluent was discarded, the plate was washed three times with 1× PBST, and 100 μL / well of SA-HRP diluted in 1% BSA / PBS was added and incubated at room temperature for 1 hour. Discard the SA-HRP diluent, wash three times with 1× PBST, add 100 μL / well of ELISA developer solution and incubate at room temperature for 1-3 minutes. Add 50 μL / well of ELISA stop buffer and read the absorbance at 450 nm. Use Graphpad software to plot the concentration-absorbance binding curve.
[0199] The results are shown in Figure 12. The anti-TIGIT-anti-PVRIG bispecific antibodies TP-007-008, TP-003-009, and TP-001-002-003 of the present invention can simultaneously bind to human TIGIT and human PVRIG proteins.
[0200] Example 6: Blocking activity of anti-TIGIT-anti-PVRIG bispecific antibody on TIGIT / CD155 and PVRIG / CD112 signaling pathways in a luciferase reporter gene system
[0201] To further detect the activity of the anti-TIGIT-anti-PVRIG bispecific antibody in simultaneously blocking the TIGIT / CD155 and PVRIG / CD112 signaling pathways at the cellular level, the following luciferase reporter gene system was constructed in this example. Briefly, lentiviral transfection cells were used to construct a CHO-K1 cell line (CHO-K1-CD155-CD112-aAPC) overexpressing human CD155, human CD112, and anti-CD3 scFv, and a Jurkat cell line (Jurkat-TIGIT-PVRIG-NF-AT-luc) overexpressing human TIGIT, human PVRIG, and NF-AT luciferase reporter genes (purchased from Promega). This reporter gene system was subsequently used to carry out related experiments.
[0202] Specifically, CHO-K1-CD155-CD112-aAPC functional cells were digested and harvested, then the cell density was adjusted and 100 μL / well was added to a 96-well white-bottom plate. The cells were cultured overnight. The next day, a Jurkat-TIGIT-PVRIG-NF-AT-luc effector cell suspension was prepared and the sample to be tested was serially diluted with reaction medium. The white-bottom plate was removed, the culture supernatant was aspirated, and 40 μL / well of the diluted sample was added to the white-bottom plate. At the same time, 40 μL / well of the Jurkat-TIGIT-PVRIG-NF-AT-luc effector cell suspension was added. The cells were incubated at 37°C, 5% CO2 for 6 hours, during which time the Bio-Glo™ reagent was allowed to return to room temperature. After the incubation period, the cells were removed, equilibrated at room temperature for 5 minutes, and 80 μL / well of the Bio-Glo™ reagent was added. The fluorescence signal was read using a multi-function microplate reader.
[0203] The results are shown in Figure 13. The results showed that the anti-TIGIT-anti-PVRIG bispecific antibodies TP-007-008, TP-003-009, and TP-001-002-003 of the present invention can respectively eliminate the CD155-mediated TIGIT downstream inhibitory signaling pathway and the CD112-mediated PVRIG downstream inhibitory signaling pathway, upregulate the expression of the reporter gene luciferase, and the blocking activity of TP-007-008 is similar to that of the combined use of two single-terminal antibody molecules.
[0204] Example 7: Luciferase reporter gene system detection of the combined blocking effect of anti-TIGIT-anti-PVRIG bispecific antibody and anti-PD-1 / L1 antibody
[0205] To detect the synergistic combined blocking activity of the anti-TIGIT-anti-PVRIG bispecific antibody and the anti-PD-1 / anti-PD-L1 antibody at the cellular level, the following luciferase reporter gene system was constructed in this example, which is briefly described as follows: Based on Example 6, CHO-K1-CD155-CD112-aAPC were lentivirally infected to overexpress PD-L1 to obtain CHO-K1-CD155-CD112-PD-L1-aAPC functional cells, and Jurkat-TIGIT-PVRIG-NF-AT-luc were lentivirally infected to overexpress PD-1 to obtain Jurkat-TIGIT-PVRIG-PD-1-NF-AT-luc effector cells. This reporter gene system was subsequently used to carry out relevant experiments.
[0206] Specifically, CHO-K1-CD155-CD112-PD-L1-aAPC functional cells were digested and the cell density was adjusted. 100 μL / well was added to a 96-well white-bottom plate and cultured overnight. The next day, a Jurkat-TIGIT-PVRIG-PD-1-NF-AT-luc effector cell suspension was prepared, and the sample to be tested was serially diluted with reaction medium. The white-bottom plate was removed, the culture supernatant was aspirated, and 40 μL / well of the diluted sample was added to the white-bottom plate. At the same time, 40 μL / well of the Jurkat-TIGIT-PVRIG-PD-1-NF-AT-luc effector cell suspension was added and placed in a 37°C, 5% CO2 incubator for 6 hours. After the culture was completed, 80 μL / well was added to the Bio-Glo™ reagent, and the fluorescence signal value was read using a multi-function microplate reader.
[0207] The results are shown in Figures 14A to 14B. The results show that the anti-TIGIT-anti-PVRIG bispecific antibodies TP-007-008, TP-003-009, and TP-001-002-003 of the present invention, in combination with the anti-PD-1 antibody Pembrolizumab (Pembro) or the anti-PD-L1 antibody Atezolizumab (ATE) at a molar ratio of 1:1, can synergistically block the downstream inhibitory signals mediated by PVRIG / CD112, TIGIT / CD155, and PD-1 / PD-L1, respectively, and further enhance the expression of the reporter gene luciferase.
[0208] Example 8: In vivo pharmacodynamic study of anti-TIGIT-anti-PVRIG bispecific antibodies in B-NDG mice co-inoculated with A375 and human PBMCs
[0209] This experiment measured the anti-tumor activity of the anti-TIGIT-anti-PVRIG bispecific antibody of the present invention in a model (A375huPBMC model) in which B-NDG mice were co-inoculated with A375 (purchased from Addexbio, C0020004, a human malignant melanoma cell line) and human PBMC (Shanghai Miaoshun, A10S033014 / PB100C). Humanized tumor mouse models with partial reconstitution of the human immune system were generated by inoculating human immune cells (PBMC) into immunodeficient mice.
[0210] Specifically, A375 cells and human PBMC were mixed in equal volumes of 1:1 to form a 0.1 mL cell suspension. The A375huPBMC model was established by subcutaneous injection into the right ventral groove of mice. 3Around 6:00 p.m., mice were divided into groups and given intraperitoneal injections of different doses of PBS or antibody at the same volume, with six mice per group. Tumor volume and body weight were monitored every 2-3 days for 2 to 3 weeks. Dosage and administration methods are shown in Table 5.
[0211] Table 5: Dosing regimen for the anti-TIGIT-anti-PVRIG bispecific antibody A375huPBMC model
[0212] Note: The molecular weights of TP-001-002-003, TP-003-009, TP-007-008, ADI-55796, and ADI-56127 are approximately 150KD, 200KD, 200KD, 150KD, and 150KD, respectively. The dosage is based on the equimolar concentration of each component.
[0213] The results are shown in Figure 15. The results show that the anti-TIGIT-anti-PVRIG bispecific antibodies TP-007-008 and TP-003-009 of the present invention have significant anti-tumor effects, and the tumor inhibition effect is comparable to that of the combination of two single-terminal antibody molecules.
[0214] Example 9: In vivo pharmacodynamic study of anti-TIGIT-anti-PVRIG bispecific antibody combined with anti-PD-1 monoclonal antibody in B-NDG mice co-inoculated with A375 and human PBMC
[0215] In this experiment, the A375huPBMC model was established by subcutaneous mixed inoculation (the modeling steps were the same as those in Example 8). 3 Around 6:00 p.m., mice were divided into groups and given different doses of PBS or antibody treatment by intraperitoneal injection at the same volume. Tumor volume and body weight changes were monitored every 2-3 days for 2 to 3 weeks. Dosage and administration methods are shown in Table 6.
[0216] Table 6: Anti-TIGIT-anti-PVRIG dual-antibody tumor inhibitory activity test plan
[0217] To further investigate the dose-dependent efficacy of the anti-TIGIT-anti-PVRIG bispecific antibody TP-007-008 combined with anti-PD-1 monoclonal antibody, the following experimental protocol was designed: an A375huPBMC model was established by subcutaneous mixed inoculation (the modeling steps were the same as in Example 8). 3Mice were divided into groups around 40 days of age and treated intraperitoneally with varying doses of TP-007-008 combined with a fixed dose of an anti-PD-1 antibody, with six mice per group. Tumor volume and body weight were monitored every two to three days for two to three weeks. Dosage and administration methods are shown in Table 7.
[0218] Table 7: Anti-TIGIT-anti-PVRIG dual-antibody tumor inhibitory activity test plan
[0219] The results are shown in Figure 16A. When the initial tumor volume reached 200 mm 3 As described above, no significant anti-tumor efficacy was observed in the anti-TIGIT-anti-PVRIG bispecific antibody TP-007-008, anti-PD-1 monoclonal antibody, and combination of anti-TIGIT and anti-PVRIG monoclonal antibodies of the present invention. However, TP-007-008 significantly inhibited tumor growth when combined with anti-PD-1 monoclonal antibody, and exhibited similar efficacy to the combination of anti-PD-1, anti-TIGIT, and anti-PVRIG monoclonal antibodies. As shown in Figure 16B, the anti-TIGIT-anti-PVRIG bispecific antibody TP-007-008, in combination with a fixed dose of PD-1 monoclonal antibody (3 mg / kg), exhibited significant dose-dependent tumor inhibitory activity.
[0220] The sequence of the anti-PD-1 monoclonal antibody used in this example is as follows:
[0221] Anti-PD-1 antibody VH amino acid sequence
[0222] Anti-PD-1 antibody VL amino acid sequence
[0223] The CDRs of the above-mentioned anti-PD-1 antibody are as follows:
[0224] HCDR1:YTFTEYYIY(SEQ ID NO:36)
[0225] HCDR2: GINPSNGGTNFNEKFKP(SEQ ID NO:37)
[0226] HCDR3:TVRDFRFDKGFKY(SEQ ID NO:38)
[0227] LCDR1:RASKSVSTSGLNYVH(SEQ ID NO:39)
[0228] LCDR2:LGSYLDS (SEQ ID NO:40)
[0229] LCDR3: QQSWELPLT(SEQ ID NO:41)
[0230] The heavy chain constant region of the anti-PD-1 monoclonal antibody used in this example adopts the IgG1 heavy chain constant region modified by L234A and L235A:
[0231] The anti-PD-1 monoclonal antibody heavy chain constant region used in this example adopts the human kappa light chain constant region:
[0232] Example 10: Study on the half-life of anti-TIGIT-anti-PVRIG bispecific antibodies in mice
[0233] The half-life of the anti-TIGIT-anti-PVRIG bispecific antibody TP-007-008 of the present invention in mice was detected by a single tail vein injection method.
[0234] Specifically, the experiment used Balb / c mice (3 males and 3 females) under a 12 / 12 hour light / dark cycle, a temperature of 24°C ± 2°C, a humidity of 40%-70%, and free access to water and food. On the day of the experiment, the Balb / c mice received a single tail vein injection of the monoclonal antibody molecule at a dose of 10 mg / kg. Blood was collected from the mouse eye socket at 5 minutes, 0.5 hours, 2 hours, 6 hours, 24 hours, 48 hours, 96 hours, 168 hours, 336 hours, and 504 hours after administration. Whole blood samples were incubated at 2°C-8°C for 30 minutes, centrifuged at 12,000 rpm for 5 minutes, and serum was collected. The resulting serum was then centrifuged at 2°C-8°C, 12,000 rpm for 5 minutes, and stored at -80°C. The content of the bispecific antibody molecule in the serum was determined by ELISA (the ELISA method was the same as in Example 5).
[0235] The results are shown in Figure 17. The results showed that the half-life of the anti-TIGIT-anti-PVRIG bispecific antibody TP-007-008 of the present invention in mice after a single injection was 103 hours.
[0236] Preparation Example 1: Preparation of anti-TIGIT monoclonal antibody
[0237] The heavy chain variable regions of the anti-TIGIT monoclonal antibodies (amino acid sequences are shown in SEQ ID NOs: 1-2, respectively) were recombined into the human IgG1 heavy chain constant region and the human IgG1 heavy chain L234A and L235A modified constant regions. In addition, the light chain variable regions (amino acid sequences are shown in SEQ ID NOs: 3-4, respectively) were recombined into the human kappa light chain constant region, and the anti-TIGIT monoclonal antibodies were named 55796-G1, 55796-G1LALA, 55812-G1, and 55812-G1LALA, respectively. Transient expression and purification were performed using the HEK293 expression system. The specific operation was as follows: The pcDNA3.1 vector carrying the antibody heavy and light chains was transferred into HEK293 cells using the chemical transfection method and cultured at 37°C, 8% CO2 for 7 days. The cell fluid was collected and centrifuged at 13,000 rpm for 20 minutes. The supernatant was collected and purified by Protein A. The purity of the antibody was tested by SEC and the endotoxin content was controlled at the same time.
[0238] In this way, the anti-TIGIT monoclonal antibodies 55796-G1, 55796-G1LALA, 55812-G1, and 55812-G1LALA were prepared.
[0239] Experimental Example 1: Affinity detection of anti-TIGIT monoclonal antibodies
[0240] The biofilm optical interferometry technique (ForteBio) was used to determine the binding dissociation constant (K) of the anti-TIGIT monoclonal antibody prepared in Preparation Example 1 for human, cynomolgus monkey, and mouse TIGIT. D The Fortebio affinity assay was performed according to the existing method (Este, P et al. High throughput solution-based measurement of antibody-antigen affinity and epitope binning. Mabs, 2013.5(2): p.270-8). The amino acid sequences of the extracellular segments of human TIGIT, cynomolgus monkey TIGIT, and mouse TIGIT are shown in Table 1 above.
[0241] The monovalent affinity of intact antibodies (i.e., full-length IgG obtained from Adimab) for human, cynomolgus monkey, and mouse TIGIT-his proteins was measured: the sensor was equilibrated offline in assay buffer for 20 minutes, followed by an online measurement for 120 seconds to establish a baseline. The intact TIGIT antibody was loaded onto the AHQ sensor to a thickness of 1 nm for affinity measurement. The antibody-loaded sensor was incubated with 100 nM TIGIT-his antigen until plateau, and then the sensor was transferred to assay buffer for at least 2 minutes for dissociation rate measurement. Kinetic analysis was performed using a 1:1 binding model.
[0242] In the above determination method, the measured K D The values are shown in Table 8 below:
[0243] Table 8: K of anti-TIGIT mAbs D value Note: "NA": not available. "NB":no binding.
[0244] The results in Table 8 show that: (1) the monovalent affinity of anti-TIGIT monoclonal antibody to human TIGIT-his protein is higher than that of the control molecule Tiragolumab; (2) the monovalent affinity of anti-TIGIT monoclonal antibody to crab-eating macaque TIGIT-his protein is comparable to that of the control molecule Tiragolumab; (3) anti-TIGIT monoclonal antibodies 55796-G1 and 55796-G1LALA have cross-binding activity with mouse TIGIT.
[0245] Experimental Example 2: Binding and blocking activity of anti-TIGIT monoclonal antibodies against human / cynomolgus monkey / mouse TIGIT-overexpressing CHO cells
[0246] 2.1 Flow cytometry was used to detect the binding activity of anti-TIGIT monoclonal antibodies to human / cynomolgus monkey / mouse TIGIT overexpressed in CHO cells.
[0247] Specifically, CHO-S cells overexpressing human TIGIT (CHO-huTIGIT cells), CHO-S cells overexpressing crab-eating macaque TIGIT (CHO-cynoTIGIT cells), and CHO-S cells overexpressing mouse TIGIT (CHO-muTIGIT cells) were produced by pressure screening by transfecting the pCHO1.0 vector (purchased from Invitrogen) cloned into MCS with human TIGIT, cynomolgus macaque TIGIT, and mouse TIGIT cDNA. The expanded overexpressing cells were adjusted to an appropriate cell density and added to a 96-well flow plate. After centrifugation, gradient dilutions of the test samples were added and incubated at 4°C for 30 minutes. Wash twice with PBS, add the corresponding fluorescent secondary antibody diluted to the appropriate concentration, incubate at 4°C for 30 minutes, and wash twice with PBS. Resuspend the cells in PBS, detect on a CytoFlex flow cytometer, and calculate the corresponding MFI. Graphpad software was used for graphical analysis to obtain EC 50 The results are shown in Table 9 and Figures 18 to 20.
[0248] 2.2 Based on the flow cytometry detection method, the blocking activity of anti-TIGIT monoclonal antibodies in blocking the binding of human CD155 to human TIGIT overexpressed on CHO cells and blocking the binding of mouse CD155 to mouse TIGIT overexpressed on CHO cells was detected.
[0249] Specifically, the cell density of the expanded cultured CHO-huTIGIT cells was adjusted to 2×10 6 Cells / mL, 100 μL / well added to a 96-well flow cytometry plate, centrifuged and set aside. Purified monoclonal antibodies were diluted with PBS, starting at 400 nM and diluted 3-fold for a total of 12 points. 60 μL / well of the diluted sample was added to the above 96-well flow cytometry plate with cells and incubated at 4°C for 30 minutes. Then, 60 μL / well of human CD155 protein with Mouse IgG2a Fc Tag was added to a final concentration of 2 μg / mL, incubated at 4°C for 30 minutes, and washed twice with PBS. 100 μL / well of APC goat anti-mouse IgG antibody diluted 100-fold with PBS was added, incubated at 4°C for 30 minutes, and washed twice with PBS. 100 μL / well of PBS was added to resuspend the cells, detected on a CytoFlex flow cytometer, and the corresponding MFI was calculated.
[0250] The cell density of the expanded CHO-muTIGIT cells was adjusted to 2×10 6cells / mL, 100μL / well was added to a 96-well flow plate, centrifuged and set aside. The purified monoclonal antibody was diluted with PBS, starting from 400nM and diluted 3 times for a total of 12 points. 60μL / well of the diluted sample was added to the above 96-well flow plate with cells and incubated at 4°C for 30 minutes. Then 60μL / well of mouse CD155 protein with Mouse IgG2a Fc Tag was added to a final concentration of 2μg / mL, incubated at 4°C for 30 minutes, and washed twice with PBS. 100μL / well of APC goat anti-mouse IgG antibody diluted 100 times with PBS was added, incubated at 4°C for 30 minutes, and washed twice with PBS. 100μL / well of PBS was added to resuspend the cells, and the detection was performed on the CytoFlex flow cytometer and the corresponding MFI was calculated. Graphpad software was used for graphical analysis to obtain IC 50 The results are shown in Table 9 and Figures 21 and 22.
[0251] Table 9: Summary of the binding blocking activity of anti-TIGIT mAbs in overexpressing cells Note: "NB":no binding; and "NA":not available.
[0252] It can be seen from Table 9 and Figures 18 to 20 that the anti-TIGIT monoclonal antibodies of the present invention (1) have better binding activity to human TIGIT protein overexpressed on the surface of CHO cells than the control molecule Tiragolumab; (2) have better binding activity to crab-eating macaque TIGIT protein overexpressed on the surface of CHO cells than the control molecule Tiragolumab; (3) 55796-G1 and 55796-G1LALA have obvious binding to mouse TIGIT protein overexpressed on the surface of CHO cells.
[0253] It can be seen from Table 9 and Figures 21 to 22 that the anti-TIGIT monoclonal antibody of the present invention, (1) has a better ability to block the binding of human CD155 to the human TIGIT protein overexpressed on the surface of CHO cells than the control molecule Tiragolumab; (2) the anti-TIGIT antibody molecules 55796-G1 and 55796-G1LALA that bind to the mouse TIGIT protein overexpressed on the surface of CHO cells can significantly block the binding of mouse CD155 to the mouse TIGIT protein overexpressed on the surface of CHO cells.
[0254] Experimental Example 3: Anti-TIGIT monoclonal antibody binds to TIGIT on the surface of primary T cells
[0255] The binding activity of the invented anti-TIGIT antibody to TIGIT on the surface of activated T cells was detected based on flow cytometry.
[0256] Specifically, human PBMCs were sorted according to the protocol provided by STEMCELL (stemcell, catalog number: #17951C) to obtain human total T cells. The T cell concentration was adjusted to 1.0×10 6 1 μL of IL-2 stock solution (1 million IU) was added to the plate at a 1:1 ratio (bead-to-cell ratio) at 1:1 ratio. CD3 / CD28 Dynabeads (Gibco, Cat. No. 11132D) were added at 1:1 ratio and cultured at 37°C in a 5% CO2 incubator for 48 hours. Activated T cells were adjusted to an appropriate cell density and plated into a 96-well flow cytometer. After centrifugation, serially diluted samples were added and incubated at 4°C for 30 minutes. The cells were washed twice with PBS, and fluorescent secondary antibodies diluted to the appropriate concentration were added. The cells were incubated at 4°C for 30 minutes, followed by two washes with PBS. The cells were resuspended in PBS and analyzed on a CytoFlex flow cytometer, and the corresponding MFI was calculated.
[0257] The results are shown in Figure 23. The results showed that the anti-TIGIT antibodies 55796-G1, 55796-G1LALA, 55812-G1, and 55812-G1LALA of the present invention can bind to TIGIT molecules on the surface of T cells, and the binding activity is better than that of the control molecule Tiragolumab.
[0258] Preparation Example 2: Preparation of anti-PVRIG monoclonal antibody
[0259] The heavy chain variable region of the anti-PVRIG monoclonal antibody (amino acid sequence shown in SEQ ID NO:5) was recombined into the human IgG1 heavy chain constant region and the human IgG1 heavy chain constant region modified with L234A and L235A, respectively. Furthermore, the light chain variable region (amino acid sequence shown in SEQ ID NO:4) was recombined into the human kappa light chain constant region. The anti-PVRIG monoclonal antibodies were designated ADI-56127-G1 and ADI-56127-G1LALA, respectively. Transient expression and purification were performed using a HEK293 expression system. The specific procedure was as follows: pcDNA3.1 vectors carrying the antibody heavy and light chains were chemically transfected into HEK293 cells and cultured at 37°C, 8% CO2 for 7 days. Cells were harvested and centrifuged at 13,000 rpm for 20 minutes. The supernatant was purified by Protein A and assayed for antibody purity and endotoxin content.
[0260] In this way, anti-PVRIG monoclonal antibodies ADI-56127-G1 and ADI-56127-G1LALA were prepared.
[0261] Experimental Example 4: Binding and blocking activity of anti-PVRIG antibodies against CHO cells overexpressing human / cynomolgus monkey / mouse PVRIG
[0262] 4.1 Flow cytometry was used to detect the binding activity of anti-PVRIG antibodies to human / cynomolgus monkey / mouse PVRIG overexpressed in CHO cells.
[0263] Specifically, CHO cells overexpressing human PVRIG (CHO-huPVRIG cells), CHO cells overexpressing crab-eating macaque PVRIG (CHO-cynoPVRIG cells), and CHO cells overexpressing mouse PVRIG (CHO-muPVRIG cells) were produced by pressure screening by transfecting the pCHO1.0 vector (purchased from Invitrogen) of human PVRIG, cynomolgus macaque PVRIG, and mouse PVRIG cDNA cloned into MCS. The expanded overexpressing cells were adjusted to an appropriate cell density and added to a 96-well flow plate. After centrifugation, gradient dilutions of the test samples were added and incubated at 4°C for 30 minutes. Wash twice with PBS, add the corresponding fluorescent secondary antibody diluted to the appropriate concentration, incubate at 4°C for 30 minutes, and wash twice with PBS. Resuspend the cells in PBS, detect on a CytoFlex flow cytometer, and calculate the corresponding MFI. Graphpad software was used for graphical analysis to obtain EC 50 The results are shown in Table 10 and Figures 24 to 26.
[0264] 4.2 Flow cytometry was used to detect the activity of anti-PVRIG antibodies in blocking the binding of human PVRIG to human CD112 overexpressed on CHO cells.
[0265] Specifically, CHO cells (CHO-huCD112 cells) overexpressing human CD112 were generated by pressure screening by transfecting the pCHO1.0 vector (purchased from Invitrogen) containing human CD112 cDNA cloned into MCS. The cell density of CHO-huCD112 cells was adjusted to 2×10 6100 μL / well of the purified monoclonal antibody was added to a 96-well flow cytometer, centrifuged, and then used. 60 μL / well of the diluted sample was added to a blank 96-well flow cytometer. Then, 1 μg / mL of human PVRIG protein with a mouse IgG2a Fc tag was added to the sample at 60 μL / well. Mix well and incubate at 4°C for 30 minutes. 100 μL / well of the incubated sample was added to a 96-well flow cytometer containing CHO-huCD112 cells. The cells were incubated at 4°C for 30 minutes and washed twice with PBS. 100 μL / well of APC goat anti-mouse IgG antibody diluted 100-fold in PBS was added to the plate and incubated at 4°C for 30 minutes. The cells were washed twice with PBS. The cells were resuspended in 100 μL / well of PBS and analyzed on a CytoFlex flow cytometer, and the corresponding MFI was calculated. The results are shown in Table 10 and Figure 27.
[0266] 4.3 The activity of anti-PVRIG antibody in blocking the binding of mouse PVRIG protein to mouse CD112 protein was detected based on ELISA detection method.
[0267] Specifically, dilute the mouse CD112-his protein with 1× coating buffer to a final concentration of 1μg / mL, add 100μL / well to the ELISA plate, cover the plate, and incubate at 4°C overnight. Discard the coating solution in the ELISA plate, wash three times with 1× PBST, add 5% BSA / PBS at 200μL / well and block at room temperature for 2 hours. During the blocking period, take the sample to be tested and dilute it with 1% BSA / PBS in a gradient manner to a final volume of 60μL / well. Take the biotinylated Mouse PVRIG huFc protein and dilute it with 1% BSA / PBS to 2μg / mL, add 60μL / well to the above sample wells, mix well, and incubate at room temperature for 1 hour. Discard the blocking solution in the ELISA plate, add the above sample mixture at 100μL / well, and incubate at room temperature for 2 hours. Discard the co-incubated sample, wash three times with 1× PBST, add 100 μL / well of SA-HRP diluted in 1% BSA / PBS, and incubate at room temperature for 1 hour. Discard the SA-HRP dilution, wash three times with 1× PBST, add 100 μL / well of ELISA developer and incubate at room temperature for 1-3 minutes. Add 50 μL / well of ELISA stop buffer, and read the absorbance at 450 nm. Graphpad software was used to generate concentration-absorbance binding curves. The results are shown in Table 10 and Figure 28.
[0268] Table 10: Summary of Anti-PVRIG Antibody Binding Blocking Activity in Overexpressed Cells Note: "NB": no binding; "NA": not available.
[0269] The following conclusions can be drawn from Table 10 and Figures 24 to 26:
[0270] (1) The binding activity of ADI-56127-G1 and ADI-56127-LALA to human PVRIG protein overexpressed on the surface of CHO cells was better than that of the control molecules Mab46-G1, Mab46-G1LALA, and COM701-G4;
[0271] (2) The binding activity of ADI-56127-G1 and ADI-56127-LALA to the cynomolgus monkey PVRIG protein overexpressed on the surface of CHO cells was superior to that of the control molecules Mab46-G1, Mab46-G1LALA, and COM701-G4;
[0272] (3) ADI-56127-G1 and ADI-56127-LALA showed significant binding to mouse PVRIG protein overexpressed on the surface of CHO cells, and the binding activity was comparable to that of the control molecules Mab46-G1 and Mab46-G1LALA.
[0273] The following conclusions can be drawn from Table 10 and Figures 27 and 28:
[0274] (1) The activity of ADI-56127-G1 and ADI-56127-LALA in blocking the binding of human PVRIG to human CD112 protein overexpressed on the surface of CHO cells was comparable to that of the control molecules Mab46-G1, Mab46-G1LALA, and COM701-G4;
[0275] (2) ADI-56127-G1 and ADI-56127-G1LALA can significantly block the binding of mouse PVRIG to mouse CD112 protein, and the blocking activity is better than that of the control molecules Mab46-G1 and Mab46-G1LALA.
[0276] Experimental Example 5: Anti-PVRIG Antibody Binds to PVRIG on the Surface of Primary T Cells
[0277] The binding activity of the anti-PVRIG antibody of the invention to PVRIG on the surface of activated T cells was detected based on flow cytometry.
[0278] Specifically, human PBMCs were sorted according to the protocol provided by STEMCELL (stemcell, catalog number: #17951C) to obtain human total T cells. The T cell concentration was adjusted to 1.0×10 6cells / mL, 1 μL of IL-2 stock solution (1 million IU) was added, and CD3 / CD28 Dynabeads (purchased from Gibco, Cat. No. 11132D) were added at a 1:1 ratio (bead-to-cell). The cells were cultured at 37°C in a 5% CO2 incubator for 48 hours. Activated T cells were adjusted to an appropriate cell density and added to a 96-well flow cytometer. After centrifugation, serially diluted samples were added and incubated at 4°C for 30 minutes. The cells were washed twice with PBS, and fluorescent secondary antibodies diluted to the appropriate concentration were added. The cells were incubated at 4°C for 30 minutes, and then washed twice with PBS. The cells were resuspended in PBS, analyzed on a CytoFlex flow cytometer, and the corresponding MFI was calculated.
[0279] The results are shown in Figure 29. The results show that the anti-PVRIG antibodies ADI-56127-G1 and ADI-56127-G1LALA of the present invention can bind to PVRIG molecules on the surface of activated T cells, and the binding activity is better than that of the control molecules Mab46-G1, Mab46-G1LALA, and COM701-G4.
[0280] Experimental Example 6: In vivo pharmacodynamic study of anti-PVRIG antibody in NDG mice inoculated with A375 and human PBMC
[0281] This study determined the anti-tumor effects of the anti-PVRIG antibodies of the present invention in a model in which B-NDG mice were co-inoculated with A375 (purchased from Addexbio, C0020004, a human malignant melanoma cell line) and human PBMC (Shanghai Miaoshun, A10S033014 / PB100C) (A375huPBMC model). Human immune cells (PBMCs) were inoculated into immunodeficient mice to generate a humanized tumor mouse model with partial reconstitution of the human immune system.
[0282] Specifically, A375 cells and human PBMC were mixed in equal volumes at a ratio of 1:1 to form a 0.1 mL cell suspension, which was then injected subcutaneously into the right ventral groove of mice to establish the A375huPBMC model. 3 Around 6:00 p.m., mice were divided into groups and given different doses of PBS or antibody treatment by intraperitoneal injection at the same volume, with 6 mice per group. Tumor volume and body weight changes were monitored every 2-3 days for 2 to 3 weeks. The dosage and method of administration are shown in Table 11.
[0283] Table 11: Dosing regimen for anti-PVRIG antibody A375 PBMC model
[0284] The results are shown in Figure 30. The results showed that the anti-PVRIG antibody ADI-56127-G1 of the present invention can significantly inhibit the growth of mouse A375 tumors, and its anti-tumor activity is better than that of the control molecules Mab46-G1 and COM701-G4.
[0285] Although specific embodiments of the present invention have been described in detail, it will be understood by those skilled in the art that various modifications and substitutions may be made to those details in light of all the teachings disclosed herein, and such modifications are within the scope of the present invention. The full scope of the present invention is given by the appended claims and any equivalents thereof.
Claims
1. A bispecific antibody comprising: Targeting the first protein domain of PVRIG, and Targeting a second protein domain that is distinct from PVRIG (e.g., TIGIT); in: The first protein functional region is an anti-PVRIG immunoglobulin or an antigen-binding fragment thereof; The heavy chain variable region of the anti-PVRIG immunoglobulin comprises HCDR1 with an amino acid sequence as shown in SEQ ID NO: 25, HCDR2 with an amino acid sequence as shown in SEQ ID NO: 26, and HCDR3 with an amino acid sequence as shown in SEQ ID NO: 27; and The light chain variable region of the anti-PVRIG immunoglobulin comprises LCDR1 with an amino acid sequence as shown in SEQ ID NO: 22, LCDR2 with an amino acid sequence as shown in SEQ ID NO: 23, and LCDR3 with an amino acid sequence as shown in SEQ ID NO:
24.
2. The bispecific antibody according to claim 1, wherein The second protein functional region is an anti-TIGIT immunoglobulin or an antigen-binding fragment thereof, wherein: The heavy chain variable region of the anti-TIGIT immunoglobulin comprises an HCDR1 with an amino acid sequence as shown in SEQ ID NO: 13, an HCDR2 with an amino acid sequence as shown in SEQ ID NO: 14, and an HCDR3 with an amino acid sequence as shown in SEQ ID NO: 15; and the light chain variable region of the anti-TIGIT immunoglobulin comprises an LCDR1 with an amino acid sequence as shown in SEQ ID NO: 16, an LCDR2 with an amino acid sequence as shown in SEQ ID NO: 17, and an LCDR3 with an amino acid sequence as shown in SEQ ID NO: 18; or, The heavy chain variable region of the anti-TIGIT immunoglobulin comprises HCDR1 as shown in SEQ ID NO:19, HCDR2 as shown in SEQ ID NO:20, and HCDR3 as shown in SEQ ID NO:21; and the light chain variable region of the anti-TIGIT immunoglobulin comprises LCDR1 as shown in SEQ ID NO:22, LCDR2 as shown in SEQ ID NO:23, and LCDR3 as shown in SEQ ID NO:
24.
3. The bispecific antibody according to any one of claims 1 to 2, wherein The antigen-binding fragments are independently single-chain antibodies or half-molecule monovalent antibodies (IgG half molecule, IgG-HM).
4. The bispecific antibody according to any one of claims 1 to 3, wherein The first protein functional region is an anti-PVRIG immunoglobulin, and the second protein functional region is an anti-TIGIT single-chain antibody; wherein: The heavy chain variable region of the anti-PVRIG immunoglobulin comprises HCDR1 as shown in SEQ ID NO: 25, HCDR2 as shown in SEQ ID NO: 26, and HCDR3 as shown in SEQ ID NO: 27; and the light chain variable region of the anti-PVRIG immunoglobulin comprises LCDR1 as shown in SEQ ID NO: 22, LCDR2 as shown in SEQ ID NO: 23, and LCDR3 as shown in SEQ ID NO: 24; and The anti-TIGIT single-chain antibody, whose heavy chain variable region comprises HCDR1 with an amino acid sequence as shown in SEQ ID NO: 13, HCDR2 with an amino acid sequence as shown in SEQ ID NO: 14, and HCDR3 with an amino acid sequence as shown in SEQ ID NO: 15; and the light chain variable region of the anti-TIGIT immunoglobulin comprises LCDR1 with an amino acid sequence as shown in SEQ ID NO: 16, LCDR2 with an amino acid sequence as shown in SEQ ID NO: 17, and LCDR3 with an amino acid sequence as shown in SEQ ID NO: 18; or The anti-TIGIT single-chain antibody, whose heavy chain variable region comprises HCDR1 as shown in SEQ ID NO:19, HCDR2 as shown in SEQ ID NO:20, and HCDR3 as shown in SEQ ID NO:21; and the light chain variable region of the anti-TIGIT immunoglobulin comprises LCDR1 as shown in SEQ ID NO:22, LCDR2 as shown in SEQ ID NO:23, and LCDR3 as shown in SEQ ID NO:
24.
5. The bispecific antibody according to any one of claims 1 to 3, wherein The first protein functional region is an anti-PVRIG single-chain antibody, and the second protein functional region is an anti-TIGIT immunoglobulin; wherein: The heavy chain variable region of the anti-PVRIG single-chain antibody comprises an HCDR1 with an amino acid sequence as shown in SEQ ID NO: 25, an HCDR2 with an amino acid sequence as shown in SEQ ID NO: 26, and an HCDR3 with an amino acid sequence as shown in SEQ ID NO: 27; and the light chain variable region of the anti-PVRIG immunoglobulin comprises an LCDR1 with an amino acid sequence as shown in SEQ ID NO: 22, an LCDR2 with an amino acid sequence as shown in SEQ ID NO: 23, and an LCDR3 with an amino acid sequence as shown in SEQ ID NO: 24; and The anti-TIGIT immunoglobulin, whose heavy chain variable region comprises an amino acid sequence as shown in SEQ ID NO: 13, an amino acid sequence as shown in SEQ ID NO: 14, and an amino acid sequence as shown in SEQ ID NO:
15. NO:15; and the light chain variable region of the anti-TIGIT immunoglobulin comprises LCDR1 with an amino acid sequence as shown in SEQ ID NO:16, LCDR2 with an amino acid sequence as shown in SEQ ID NO:17, and LCDR3 with an amino acid sequence as shown in SEQ ID NO:18; or The anti-TIGIT immunoglobulin has a heavy chain variable region comprising an HCDR1 with an amino acid sequence as shown in SEQ ID NO: 19, an HCDR2 with an amino acid sequence as shown in SEQ ID NO: 20, and an HCDR3 with an amino acid sequence as shown in SEQ ID NO: 21; and the light chain variable region of the anti-TIGIT immunoglobulin comprises an LCDR1 with an amino acid sequence as shown in SEQ ID NO: 22, an LCDR2 with an amino acid sequence as shown in SEQ ID NO: 23, and an LCDR3 with an amino acid sequence as shown in SEQ ID NO:
24.
6. The bispecific antibody according to any one of claims 1 to 5, wherein The amino acid sequence of the heavy chain variable region of the anti-PVRIG immunoglobulin or anti-PVRIG single-chain antibody is shown in SEQ ID NO: 5; and The amino acid sequence of the light chain variable region of the anti-PVRIG immunoglobulin or anti-PVRIG single-chain antibody is shown in SEQ ID NO: 4; Preferably, the glycine at position 44 of the heavy chain variable region of the anti-PVRIG immunoglobulin or anti-PVRIG single-chain antibody is replaced by cysteine, and the glycine at position 100 of the light chain variable region of the anti-PVRIG immunoglobulin or anti-PVRIG single-chain antibody is replaced by cysteine.
7. The bispecific antibody according to any one of claims 1 to 6, wherein The amino acid sequence of the heavy chain variable region of the anti-TIGIT immunoglobulin or anti-TIGIT single-chain antibody is shown in SEQ ID NO: 1; and the amino acid sequence of the light chain variable region of the anti-TIGIT immunoglobulin or anti-TIGIT single-chain antibody is shown in SEQ ID NO: 2; or, The amino acid sequence of the heavy chain variable region of the anti-TIGIT immunoglobulin or anti-TIGIT single-chain antibody is shown in SEQ ID NO: 3; and the amino acid sequence of the light chain variable region of the anti-TIGIT immunoglobulin or anti-TIGIT single-chain antibody is shown in SEQ ID NO: 4; Preferably, the glycine at position 44 of the heavy chain variable region of the anti-TIGIT immunoglobulin or anti-TIGIT single-chain antibody is replaced with cysteine, and the glycine at position 100 of the light chain variable region of the anti-TIGIT immunoglobulin or anti-TIGIT single-chain antibody is replaced with cysteine.
8. The bispecific antibody according to any one of claims 1 to 7, wherein The first protein functional region and the second protein functional region are directly connected or connected through a connecting fragment; Preferably, the linker fragment is (GGGGS)m, where m is a positive integer, such as 1, 2, 3, 4, 5 or 6; Preferably, the amino acid sequence of the connecting fragment is shown in SEQ ID NO:
6.
9. The bispecific antibody according to any one of claims 1 to 8, wherein The first protein functional region and the second protein functional region are independently 1, 2 or more.
10. The bispecific antibody according to any one of claims 1 to 9, wherein: The anti-TIGIT single-chain antibody is respectively connected to the C-termini of the two heavy chains of the anti-PVRIG immunoglobulin; or The anti-PVRIG single-chain antibody is respectively connected to the C-termini of the two heavy chains of the anti-TIGIT immunoglobulin.
11. The bispecific antibody according to any one of claims 1 to 10, wherein The constant region of the anti-PVRIG immunoglobulin or anti-TIGIT immunoglobulin is derived from a human antibody; Preferably, the constant region is independently selected from the constant region of human IgG1, IgG2, IgG3 or IgG4.
12. The bispecific antibody according to any one of claims 1 to 11, wherein The heavy chain constant region of the anti-PVRIG immunoglobulin or anti-TIGIT immunoglobulin is human Ig gamma-1 chain C region or human Ig gamma-4 chain C region, and the light chain constant region thereof is human Ig kappa chain C region; Preferably, the heavy chain constant region of the anti-PVRIG immunoglobulin and anti-TIGIT immunoglobulin further comprises an L234A mutation and an L235A mutation according to the EU numbering system.
13. The bispecific antibody according to any one of claims 1 to 12, which is a dimer or tetramer of two peptide chains with amino acid sequences as shown in SEQ ID NO: 7 and SEQ ID NO: 8, or a dimer or tetramer of two peptide chains with amino acid sequences as shown in SEQ ID NO: 9 and SEQ ID NO:
10.
14. An isolated nucleic acid molecule encoding the bispecific antibody of any one of claims 1 to 13.
15. A vector comprising the isolated nucleic acid molecule of claim 14.
16. A host cell comprising the isolated nucleic acid molecule of claim 14, or the vector of claim 15.
17. A conjugate comprising a bispecific antibody and a conjugated moiety, wherein: The bispecific antibody is the bispecific antibody according to any one of claims 1 to 13, and the coupling moiety is a detectable label; preferably, the coupling moiety is a radioisotope, a fluorescent substance, a colored substance or an enzyme.
18. A kit comprising the bispecific antibody according to any one of claims 1 to 13, or the conjugate according to claim 17; Preferably, the kit further comprises a second antibody capable of specifically binding to the bispecific antibody; optionally, the second antibody further comprises a detectable label, such as a radioisotope, a fluorescent substance, a colored substance or an enzyme.
19. A pharmaceutical composition comprising the bispecific antibody according to any one of claims 1 to 13, and one or more pharmaceutically acceptable excipients; Preferably, the pharmaceutical composition further comprises at least one anti-PD-1 antibody; Preferably, the molar ratio of the bispecific antibody to the anti-PD-1 antibody is (1:5) to (5:1), more preferably 1:
1.
20. The pharmaceutical composition according to claim 19, wherein The anti-PD-1 antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises HCDR1 to HCDR3, and the light chain variable region comprises LCDR1 to LCDR3, wherein: The amino acid sequence of HCDR1 is shown in SEQ ID NO:36, the amino acid sequence of HCDR2 is shown in SEQ ID NO:37, the amino acid sequence of HCDR3 is shown in SEQ ID NO:38, the amino acid sequence of LCDR1 is shown in SEQ ID NO:39, the amino acid sequence of LCDR2 is shown in SEQ ID NO:40, and the amino acid sequence of LCDR3 is shown in SEQ ID NO:41; Preferably, the amino acid sequence of the heavy chain variable region of the anti-PD-1 antibody is shown in SEQ ID NO: 34, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:
35.
21. A combination product comprising a first product and a second product in separate packages, wherein: The first product comprises the bispecific antibody according to any one of claims 1 to 13; The second product comprises at least one anti-PD-1 antibody; Preferably, the first product and the second product further independently contain one or more pharmaceutically acceptable excipients; Preferably, the combination product further comprises product instructions; Preferably, the molar ratio of the bispecific antibody to the anti-PD-1 antibody is (1:5) to (5:1), more preferably 1:
1.
22. The combination product according to claim 21, wherein The anti-PD-1 antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises HCDR1 to HCDR3, and the light chain variable region comprises LCDR1 to LCDR3, wherein: The amino acid sequence of HCDR1 is shown in SEQ ID NO:36, the amino acid sequence of HCDR2 is shown in SEQ ID NO:37, the amino acid sequence of HCDR3 is shown in SEQ ID NO:38, the amino acid sequence of LCDR1 is shown in SEQ ID NO:39, the amino acid sequence of LCDR2 is shown in SEQ ID NO:40, and the amino acid sequence of LCDR3 is shown in SEQ ID NO:41; Preferably, the amino acid sequence of the heavy chain variable region of the anti-PD-1 antibody is shown in SEQ ID NO: 34, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:
35.
23. Use of the bispecific antibody according to any one of claims 1 to 13 or the conjugate according to claim 17 in the preparation of a medicament for treating or preventing tumors; Preferably, the tumor is selected from one or more of colon cancer, melanoma, lung cancer, kidney cancer, endometrial cancer, breast cancer, skin cancer, ovarian cancer, gastric cancer, head and neck cancer, liver cancer, brain tumor, urothelial cancer, bone tumor, bile duct cancer, rectal cancer, pancreatic cancer, cervical tumor, multiple myeloma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, B lymphocytic neoplasm, plasma cell cancer, prostate cancer and testicular cancer; Preferably, the lung cancer is non-small cell lung cancer or small cell lung cancer.
24. The bispecific antibody according to any one of claims 1 to 13 or the conjugate according to claim 17, for use in treating or preventing tumors; Preferably, the tumor is selected from colon cancer, melanoma, lung cancer, kidney cancer, endometrial cancer, breast cancer, one or more of skin cancer, ovarian cancer, stomach cancer, head and neck cancer, liver cancer, brain tumor, urothelial cancer, bone tumor, bile duct cancer, rectal cancer, pancreatic cancer, cervical cancer, multiple myeloma, Hodgkin lymphoma, non-Hodgkin lymphoma, B lymphocytic neoplasm, plasma cell cancer, prostate cancer, and testicular cancer; Preferably, the lung cancer is non-small cell lung cancer or small cell lung cancer.
25. A method for treating or preventing tumors, comprising the step of administering to a subject in need thereof an effective amount of the bispecific antibody according to any one of claims 1 to 13 or the conjugate according to claim 17; Preferably, the tumor is selected from one or more of colon cancer, melanoma, lung cancer, kidney cancer, endometrial cancer, breast cancer, skin cancer, ovarian cancer, gastric cancer, head and neck cancer, liver cancer, brain tumor, urothelial cancer, bone tumor, bile duct cancer, rectal cancer, pancreatic cancer, cervical tumor, multiple myeloma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, B lymphocytic neoplasm, plasma cell cancer, prostate cancer and testicular cancer; Preferably, the lung cancer is non-small cell lung cancer or small cell lung cancer.
Citation Information
Cited By
Antibody or antigen binding fragment targeting CD155 and application thereof
CN119431583A
